A Randomized Phase III Trial of Hypofractionated Post-Prostatectomy Radiation Therapy (HYPORT) Versus Conventional Post-Prostatectomy Radiation Therapy (COPORT)
Phase: PHASE3
Conditions: Prostate Adenocarcinoma, Stage I Prostate Adenocarcinoma AJCC v7, Stage II Prostate Adenocarcinoma AJCC v7, Stage III Prostate Adenocarcinoma AJCC v7
Sponsor: NRG Oncology

NRG ONCOLOGY 
 
NRG-GU003 
 
(ClinicalTrials.gov NCT #: 03274687) 
 
 
A RANDOMIZED PHASE III TRIAL OF HYPOFRACTIONATED POST-
PROSTATECTOMY RADIATION THERAPY (HYPORT) VERSUS CONVENTIONAL 
POST-PROSTATECTOMY RADIATION THERAPY (COPORT) 
 
 
 
Amendment 1:  April 26, 2019 

NRG-GU003 
1  
Version Date: April 26, 2019   
 
 
 NRG ONCOLOGY 
 
NRG-GU003  
(ClinicalTrials.gov NCT # 03274687)(26-APR-2019) 
 
A RANDOMIZED PHASE III TRIAL OF HYPOFRACTIONATED POST-
PROSTATECTOMY RADIATION THERAPY (HYPORT) VERSUS CONVENTIONAL 
POST-PROSTATECTOMY RADIATION THERAPY (COPORT) 
 
This trial is part of the National Clinical Trials Network (NCTN) program, which is sponsored 
by the National Cancer Institute (NCI). The trial will be led by NRG Oncology with the 
participation of the network of NCTN organizations: the Alliance for Clinical Trials in 
Oncology; ECOG-ACRIN Medical Group; and SWOG.  
 
Coordinating Center:  
NRG Oncology 
Four Penn Center; 1600 JFK Blvd; Suite 1020; Philadelphia, PA 19103 
 
Study Team (26-APR-2019) 
Principal Investigator/Radiation Oncology 
Mark Buyyounouski, MD, MS 
Stanford University, Department of Radiation 
Oncology 
875 Blake Wilbur Drive, MC5847 
Stanford, CA 94305-5847 
(650) 723-6171/Fax: (650) 725-8231 
mark.buyyounouski@stanford.edu 
Radiation Oncology and Quality of Life and 
Comparative Effectiveness Research 
Ronald Chen, MD, MPH 
University of North Carolina Chapel Hill 
101 Manning Drive 
Chapel Hill, NC 28223 
(984) 974-0400/Fax: (984) 974-8607 
ronald_chen@med.unc.edu 
Translational Science Co-chair 
Felix Feng, MD 
University of California, San Francisco 
1825 4th Street, First floor, Rm M2267 
San Francisco, CA 94143 
8415-353-7183/Fax: 415-353-7182 
Felix.Feng@ucsf.edu  
Medical Physics 
Rajat J. Kudchadker, PhD 
University of Texas MD Anderson Cancer 
Ctr 
6767 Bertner Ave, Mitchell Bldg BSRB 
Houston, TX 77030 
(713) 563-2538/Fax: 713-563-6949 
rkudchad@mdanderson.org 
Urology 
Mark Mann, MD 
Thomas Jefferson University Hospital 
833 Chestnut St, Suite 703 
Philadelphia, PA 19107 
Ph: (215) 955-1000/Fax: (215) 503-2066 
mark.mann@jefferson.edu 
Modality Co-Chair/Health Utilities 
Andre A. Konski, MD, MBA, MA, FACR 
Department of Radiation Oncology 
University of Pennsylvania 
Chester County Hospital 
701 East Marshall St, West Chester, PA  
610-431-5530 
andre.konski@uphs.upenn.edu  
Study Team continued on next page 

NRG-GU003 
2  
Version Date: April 26, 2019   
NRG ONCOLOGY  
 
NRG-GU003  
 
A RANDOMIZED PHASE III TRIAL OF HYPOFRACTIONATED POST-
PROSTATECTOMY RADIATION THERAPY (HYPORT) VERSUS CONVENTIONAL 
POST-PROSTATECTOMY RADIATION THERAPY (COPORT) 
 
Study Team continued 
Statistician 
Stephanie Pugh, PhD 
NRG Oncology 
1818 Market Street, Suite 1720 
Philadelphia, PA 19103 
215-717-0850 
pughs@nrgoncology.org  
 
 
The following NCTN Group Study Champions have been added to this trial: 
ECOG-ACRIN 
Neha Vapiwala, MD 
University of Pennsylvania 
Abramson Cancer Center 
Perelman Center for Advanced Medicine/ 
Radiation Oncology 
3400 Civic Center Boulevard 
Fourth Floor West 
Philadelphia, PA 19104 
2145-662-7296 
vapiwala@uphs.upenn.edu  
SWOG 
David Raben, MD 
University of Colorado Cancer Center  
Department of Radiation Oncology  
1665 Aurora Court, Suite 1032 MS F706 
Aurora, CO 80045  
720-848-0154  
David.raben@ucdenver.edu  
 
 
 
 
 
 
 
 
 
 
 

NRG-GU003 
3  
Version Date: April 26, 2019   
NRG Oncology Contact Information 
Data Managers:   
For questions concerning eligibility or 
data submission 
Elaine Motyka-Welsh, RN, MSN, CCRP 
NRG Oncology 
1818 Market Street, Suite 1720 
Philadelphia, PA 19003 
215-574-3216 
motyka-welshe@nrgoncology.org  
 
Roseann Bonanni, CTR, CCRP 
NRG Oncology 
1818 Market Street, Suite 1720 
Philadelphia, PA 19003 
215-574-3223 
bonannir@nrgoncology.org 
 
RTQA:  
For questions concerning RT data 
submission 
Dosimetrist (RTQA questions) 
Joanne Hunter, BS, RT(T)(R) 
IROC Philadelphia-RT QA Center 
ACR Clinical Research Center 
1818 Market Street, Suite 1720 
Philadelphia, PA 19103 
215-574-3222 
jhunter@acr.org  
RTQA:   
For questions concerning data 
submission to TRIAD 
Triad-Support@acr.org 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

NRG-GU003 
4  
Version Date: April 26, 2019   
NRG ONCOLOGY  
 
NRG-GU003  
 
A RANDOMIZED PHASE III TRIAL OF HYPOFRACTIONATED POST-
PROSTATECTOMY RADIATION THERAPY (HYPORT) VERSUS CONVENTIONAL 
POST-PROSTATECTOMY RADIATION THERAPY (COPORT) 
 
 
 
 
NRG Oncology Contact Information continued 
Protocol Development: 
For questions concerning protocol and 
informed consent versions & amendments 
Carol Lam 
NRG Oncology 
1818 Market Street, Suite 1720 
Philadelphia, PA 19103 
215-717-0848 
lamc@nrgoncology.org  
Genitourinary Cancer Committee Chair 
Current Chair starting March 30, 2018: 
Felix Feng, MD 
(see Translational Science cover page for 
contact information) 
 
Prior Chair:  
Howard M. Sandler, MD, MS 
Department of Radiation Oncology 
Cedars-Sinai Medical Center 
8700 Beverly Boulevard 
Los Angeles, CA 90048 
310-423-4234/FAX 310-423-6161 
Howard.Sandler@cshs.org 
 
 
 

NRG-GU003 
5  
Version Date: April 26, 2019   
 
NRG ONCOLOGY  
 
NRG-GU003  
 
A RANDOMIZED PHASE III TRIAL OF HYPOFRACTIONATED POST-
PROSTATECTOMY RADIATION THERAPY (HYPORT) VERSUS CONVENTIONAL 
POST-PROSTATECTOMY RADIATION THERAPY (COPORT) 
 
 
 
Participating Sites 
 U.S. 
 Canada  
 Approved International Member Sites  
 
 
 
Document History 
 
VersionDate 
Broadcast Date 
Amendment 1 
April 26, 2019 
N/A 
Activation 
June 26, 2017 
July 28, 2017 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
This protocol was designed and developed by NRG Oncology. It is intended 
to be used only in conjunction with institution-specific IRB approval for 
study entry.  No other use or reproduction is authorized by NRG Oncology 
nor does NRG Oncology assume any responsibility for unauthorized use of 
this protocol. 

NRG-GU003 
6  
Version Date: April 26, 2019   
NRG ONCOLOGY 
 
NRG-GU003 
 
A RANDOMIZED PHASE III TRIAL OF HYPOFRACTIONATED POST-
PROSTATECTOMY RADIATION THERAPY (HYPORT) VERSUS CONVENTIONAL 
POST-PROSTATECTOMY RADIATION THERAPY (COPORT) 
 
CONTACT INFORMATION(26-APR-2019) 
 
For regulatory requirements: 
For patient enrollments: 
For study data submission: 
Regulatory documentation must 
be submitted to the CTSU via 
the Regulatory Submission 
Portal. : (Sign in at 
www.ctsu.org, and select the 
Regulatory Submission sub-
tab under the Regulatory 
tab.)  
 
Institutions with patients 
waiting that are unable to use 
the Portal should alert the 
CTSU Regulatory Office 
immediately at 1-866-651-2878 
to receive further instruction 
and support. 
 
Contact the CTSU Regulatory 
Help Desk at 1-866-651-2878 
for regulatory assistance. 
Please refer to the patient 
enrollment section of the protocol 
for instructions on using the 
Oncology Patient Enrollment 
Network (OPEN) which can be 
accessed at 
https://www.ctsu.org/OPEN_SYS
TEM/ or https://OPEN.ctsu.org. 
 
Contact the CTSU Help Desk 
with any OPEN-related questions 
at ctsucontact@westat.com. 
 
 
Data collection for this study 
will be done exclusively through 
Medidata Rave.  Please see the 
data submission section of the 
protocol for further instructions.  
 
The most current version of the study protocol and all supporting documents must be downloaded 
from the protocol-specific Web page of the CTSU Member Web site located at https://www.ctsu.org.  
Access to the CTSU members’ website is managed through the Cancer Therapy and Evaluation Program 
- Identity and Access Management (CTEP-IAM) registration system and requires user log on with 
CTEP-IAM username and password.  
For clinical questions, contact the Study PI of the Lead Protocol Organization. 
For questions concerning eligibility, please contact the Biostatistical/Data Management Center (via the 
contact list on the protocol cover page). For radiation therapy-related eligibility questions, please contact 
RTQA (via the contact list on the protocol cover page).  
For non-clinical questions (i.e. unrelated to patient eligibility, treatment, or clinical data 
submission) contact the CTSU Help Desk by phone or e-mail:  
CTSU General Information Line – 1-888-823-5923, or ctsucontact@westat.com.  All calls and 
correspondence will be triaged to the appropriate CTSU representative.  
The CTSU Website is located at https://www.ctsu.org. 
 
 
 

NRG-GU003 
7  
Version Date: April 26, 2019   
 
TABLE OF CONTENTS 
NRG-GU003 ....................................................................................................................................9 
SCHEMA .........................................................................................................................................9 
1. OBJECTIVES ............................................................................................................................10 
1.1 
Primary Objective ..................................................................................................10 
1.2 
Secondary Objectives.............................................................................................10 
1.3 
Exploratory Objectives ..........................................................................................10 
2. BACKGROUND .......................................................................................................................10 
2.1  
Prostate Cancer is the Second Most Common Cancer in Men ..............................10 
2.2 
Rationale for Hypofractionation ............................................................................11 
2.3 
This trial is important because: ..............................................................................15 
3. PATIENT SELECTION, ELIGIBILITY, AND INELIGIBILTY CRITERIA .........................15 
3.1 
Patient Selection Guidelines ..................................................................................15 
3.2 
Eligibility Criteria ..................................................................................................16 
3.3 
Ineligibility Criteria ...............................................................................................17 
4. REQUIREMENTS FOR STUDY ENTRY, TREATMENT, AND FOLLOW-UP ..................18 
5. TREATMENT PLAN/REGIMEN DESCRIPTION ..................................................................20 
5.1 
Chemotherapy/Hormonal Therapy/Other Agent-Based Therapy ..........................20 
5.2 
Radiation Therapy ..................................................................................................20 
5.3 
General Concomitant Medication and Supportive Care Guidelines ......................27 
5.4 
Duration of Therapy ...............................................................................................27 
6. TREATMENT MODIFICATIONS/MANAGEMENT .............................................................27 
7. 
ADVERSE EVENTS REPORTING REQUIREMENTS .................................................28 
7.1   
Protocol Agents ......................................................................................................28 
7.2  
Adverse Events and Serious Adverse Events ........................................................28 
7.3 
Expedited Reporting of Adverse Events ................................................................28 
8. 
REGISTRATION, STUDY ENTRY, AND WITHDRAWAL PROCEDURES ..............32 
8.1 
Investigator Registration Requirements ................. Error! Bookmark not defined. 
8.2 
RT-Specific Pre-Registration Requirements..........................................................34 
8.3 
Patient Enrollment .................................................................................................36 
9.0 
DRUG INFORMATION ...................................................................................................37 
9.1 
Commercial Agents. ..............................................................................................37 
10. 
PATHOLOGY/BIOSPECIMEN .......................................................................................37 
10.1 
Biospecimen Submission Tables ...........................................................................37 

NRG-GU003 
8  
Version Date: April 26, 2019   
11. 
SPECIAL studies (Non-Tissue) .........................................................................................39 
11.1 
The Expanded Prostate Cancer Index Composite (EPIC) .....................................39 
12. 
Modality Reviews ..............................................................................................................40 
12.1 
Radiation Therapy Quality Assurance Reviews ....................................................40 
13. 
DATA AND RECORDS ...................................................................................................40 
13.1 
Data Management/Collection ................................................................................40 
13.2 
Summary of Data Submission ...............................................................................40 
13.3 
Global Reporting/Monitoring ................................................................................41 
14. 
STATISTICAL CONSIDERATIONS...............................................................................41 
14.1     Study Design ..........................................................................................................41 
14.2 
Study Endpoints .....................................................................................................41 
14.3 
Primary Objectives Study Design ..........................................................................42 
14.4 
Study Monitoring of Primary Objectives ...............................................................44 
14.5 
Accrual/Study Duration Considerations ................................................................45 
14.6 
Secondary Endpoints .............................................................................................45 
14.7 
Exploratory Endpoints ...........................................................................................47 
14.8 
Gender/Ethnicity/Race Distribution.......................................................................48 
REFERENCES ..............................................................................................................................49 
 
 
 

NRG-GU003 
9  
Version Date: April 26, 2019   
NRG-GU003 
 
A RANDOMIZED PHASE III TRIAL OF HYPOFRACTIONATED POST-
PROSTATECTOMY RADIATION THERAPY (HYPORT) VERSUS CONVENTIONAL 
POST-PROSTATECTOMY RADIATION THERAPY (COPORT) 
 
SCHEMA 
 
 
STEP 1 REGISTRATION 
Completion of the Step 1 eligibility checklist then completion of the Step 1 
registration process  
  
 ↓ 
STEP 2 RANDOMIZATION 
Completion and submission of the Expanded Prostate Composite Index (EPIC) 
 
Completion and submission of the step 2 eligibility checklist 
 
STRATIFY 
 
1.  Baseline EPIC score group (A vs. B vs. C vs. D) 
 A = high bowel and urinary scores 
B = high bowel and low urinary scores 
C = low bowel and high urinary scores  
D = low bowel and urinary scores† 
 
 
2.  Androgen Deprivation Therapy (Yes vs. No) 
 
 
↓ 
↓ 
 
ARM I (COPORT) 
 
Radiation Therapy:* 
66.6 Gy in 37 fractions of 1.8 Gy to 
the prostate bed;  
EQD2 (1.5 Gy) = 63 Gy 
 
 
 
 
ARM II (HYPORT) 
 
Radiation Therapy:* 
62.5 Gy in 25 fractions of 2.5 Gy to 
the prostate bed;  
EQD2 (1.5 Gy) = 71 Gy 
 
*ADT is allowed and if given, no more than 6 months will be administered 
**Lymph node RT is not permitted. 
†High bowel score > 96, low bowel score ≤ 96, high urinary score > 84, low urinary score ≤84 
Accrual goal = 282 
 

NRG-GU003 
10  
Version Date: April 26, 2019   
 
1. OBJECTIVES 
1.1 
Primary Objective  
The primary objective is to demonstrate that hypofractionated post-prostatectomy 
radiotherapy (HYPORT) does not increase patient-reported GI and GU symptoms  over 
conventionally fractionated post-prostatectomy (COPORT) at the 2-year time point. 
 
1.2 
Secondary Objectives 
• To compare patient-reported GI symptoms using the EPIC at end of RT and 6, 12, 24, 
and 60 months from end of treatment; 
• To compare patient-reported GU symptoms using the EPIC at end of RT and 6, 12, 
24, and 60 months from end of treatment; 
• To compare time to progression (TTP) where progression is defined as the first 
occurrence of biochemical failure (BF), local failure, regional failure, distant 
metastasis (DM), institution of new unplanned anticancer treatment, or death from 
prostate cancer (PCSM); 
• To compare freedom from biochemical failure (FFBF) and TTP rates with an 
alternate PSA ≥ PSA nadir + 2 ng/mL definition of BF; 
• To compare local failure, regional failure, salvage therapy (i.e. institution of new 
unplanned anticancer treatment), DM, PCSM, and overall survival (OS) rates; 
• Assessment of adverse events; 
 
1.3 
Exploratory Objectives 
• To compare utilities for health outcomes using the EQ-5D; 
• Paraffin-embedded tissue block, serum, plasma, whole blood, and urine for future 
translational research analyses for predictors of toxicity following hypofractionated or 
conventionally fractionated post-prostatectomy radiotherapy. Note: Testing of banked 
specimens will not occur until an amendment to this treatment protocol (or separate 
correlative science protocol) is reviewed and approved in accordance with National 
Clinical Trials Network (NCTN) policies. 
 
2. BACKGROUND 
 
STUDY DISEASE 
 
2.1  
Prostate Cancer is the Second Most Common Cancer in Men 
Worldwide, prostate cancer is the second most frequently diagnosed cancer of men (1,111,689 
new cases, representing 15% of the total in 2012) and the fifth most common cancer overall.  
Prostate cancer is the sixth leading cause of death from cancer in men (6.6% of the total).  It is 
predicted that the number of cases will almost double by 2030. (GLOBOCAN 2012)  
 
Radical Prostatectomy is the Most Common Treatment for Prostate Cancer 
Radical prostatectomy is the most common treatment for prostate cancer according to the 
National Cancer Institute’s Patterns of Care study from 14 regional cancer registries.[4] The 
proportion of men undergoing prostatectomy was 70% for age <60 years, 51% for 60-64 years, 
and 39% for 65-75 years. (Hamilton 2011)  

NRG-GU003 
11  
Version Date: April 26, 2019   
 
Adjuvant and Salvage Therapy 
An estimated 15-25% of prostatectomy patients will develop a prostate specific antigen (PSA) 
recurrence. (Stephenson 2012) High-risk features for recurrence include extra-capsular extension 
and/or seminal vesicle invasion (pT3 disease) and positive surgical margins, which occur in an 
estimated 20% and 16% of patients, respectively. (Tewari 2012)  Post-prostatectomy 
radiotherapy (RT) to the prostate bed for pT3 disease or positive surgical margins has been 
shown to reduce the risk of recurrence in three randomized trials: Southwest Oncology Group 
(SWOG) (Thompson 2006); European Organization for Research and Treatment of Cancer 
(EORTC) (Bolla 2012); and Auckland Radiation Oncology (ARO). (Wiegel 2009) As a result, 
post-prostatectomy RT is a well-accepted practice standard for adverse pathologic features 
following surgery or at the first sign of PSA recurrence. (Prostate Cancer 2016, Thompson 2013)  
 
Rationale for Dose Escalation 
2.1.1  Lessons From Intact Prostate RT 
Central to the success of RT for intact prostate cancer has been dose escalation where an 
additional 8 - 10 Gy in 2 Gy fractions has been shown to effectively reduce the risk of 
biochemical failure (BF) [Dearnaley 2007, Fuks 1991, Kuban 1987, 1989, 2008, 2011, 
Zietman 2010], as well as prevent distant metastasis and death (Kuban 2011).  The 
eradication of local disease for intact prostate cancer has also been shown to reduce the 
risk of distant metastasis and death from prostate cancer (Coen 2002, Zelefsky 2008, 
Kuban 1987, Fuks 1991). Rectal complications have been the primary dose limiting 
toxicity with dose escalation.  
2.1.2  Post-prostatectomy Dose Escalation 
Radiotherapy dose escalation is rooted in the fundamental radiobiological principle that 
higher doses are needed to eradicate an increasing burden of disease (Hall 2012). A 
biochemical tumor control probability (TCP) analysis of dose–response curves for 
adjuvant and salvage post-prostatectomy RT has estimated a 3%/Gy improvement in 
FFBF with dose escalation (2.6%/Gy, 95% CI, 2.3–3.0 for adjuvant; 3.8%/Gy, 95% CI, 
2.5–7.6 for salvage) [King 2008].  Various treatment planning studies have shown that 
adequate rectal sparing for dose escalation in the > 70 Gy in 2 Gy fraction range is 
achievable with modern RT techniques employing image guidance [Bernard 2010, De 
Meerleer 2008, King 2008, Harrison 2011]. Several studies have indicated a benefit to 
dose escalation post-prostatectomy (King 2008b, King 2008a, Cozzarini 2009, Valicenti 
1998, Anscher 2000). And clinical studies have indicated the risk of toxicity with RT 
dose ≥ 70 Gy in 2 Gy fractions is low with less than 3% of late grade 3 proctitis or 
genitourinary side effects, respectively (De Meerleer 2008, Wiegel 2009, Van Der Poel 
2008, Feng 2007, Hunter 2012).  
 
2.2 
Rationale for Hypofractionation 
2.2.1 Hypofractionation Definition 
Post-prostatectomy RT has traditionally been delivered in conventional fractionation (i.e. 
1.8 or 2.0 Gy per fraction) that can take as long as 6 to 8 weeks to deliver (Thompson 
2009, Bolla 2005, Wiegel 2009). The proposed study explores an alternative RT dose-
fractionation schedule that exploits the radiobiological properties of prostate cancer to 
shorten overall treatment time called hypofractionation.  Hypofractionation uses larger 

NRG-GU003 
12  
Version Date: April 26, 2019   
daily fraction sizes (i.e. 2 to 5 Gy) to deliver a RT over a shorter duration. 
2.2.2 Hypofractionation Advantages 
The potential advantages of hypofractionation are: 1) increased convenience to patients 
because of fewer treatment days, 2) reduced cost to patients because of reduced travel 
expenses and copays, 3) improved resource utilization for physicians because of the 
fewer number of treatments per patient and overall, 4) and consequently reduced cost to 
society.  All of these factors may increase the utilization of post-prostatectomy RT, which 
is estimated to be < 20% for patients with pT3 disease and positive margins who are most 
likely to benefit, and unaltered by the results of the randomized trials (Ghia 2010, 
Hoffman 2011). In prostate cancer specifically, hypofractionation has the added potential 
advantage of not increasing toxicity (primary endpoint of Phase II) compared to standard 
fractionation, while delivering a higher biological dose and therefore increase efficacy 
(primary endpoint for Phase III). 
2.2.3 Similarities to Breast Hypofractionation 
This proposed trial mirrors the practice changing Ontario Clinical Oncology Group 
(OCOG) [Whelan 2010], UK Standardization of Breast Radiotherapy (START) Trial A 
(Bentzen 2008a), and START Trial B (Bentzen 2008b) breast cancer trials that sought the 
advantages of hypofractionation following lumpectomy for early-stage breast cancer and 
redefined the standard of care (Smith 2011). There are three important comparisons 
between the current trial and the breast trials: 1) the rationale for hypofractionation, 2) the 
reduction in overall treatment time, and 3) the primary endpoint.  Regarding the rationale, 
hypofractionation for breast cancer has evolved on an empirical basis, while prostate 
hypofractionation has evolved more closely rooted to radiobiologic modeling. 
Furthermore, the magnitude of the radiobiologic advantage for hypofractionation for 
breast cancer is three times less than that of prostate cancer.  Second, the reduction in 
overall treatment duration with breast hypofractionation is less compared to prostate 
cancer: 13-14 total treatment days for breast, and 18 days for prostate. 
Last, the primary endpoint for the breast trials employed a local control primary 
endpoint, opposed to a survival based end-point, which is similar to a BF endpoint in 
prostate cancer because both local and distant recurrences are counted.  The publication 
of the breast cancer hypofractionation trials has led to practice changes in the US and 
internationally. Therefore, similar if not more enthusiasm is expected for HYPORT that 
could also change the international standard of care. 
2.2.4 Intact Prostate Hypofractionation 
Results from definitive in-tact prostate hypofractionation from the Cleveland Clinic 
Phase II trial (Kupelian 2007, Kupelian 2005), the Fox Chase Phase III trial (Pollack 
2011, Pollack 2006), and the Italian Phase III trial (Arcangeli 2012, Arcangeli 2011, Lee 
2016) indicate that hypofractionation over 5 weeks is at least as effective and not more 
toxic than conventional fractionation with fraction sizes of 2.5 Gy, 2.7 Gy or 3.1 Gy, 
respectively.  Therefore, at least similar effectiveness with hypofractionation in the 
proposed trial is hypothesized. 
2.2.5 Preliminary HYPORT Data 
The preliminary post-prostatectomy dose-escalated hypofractionation experience from 
the University of Wisconsin has demonstrated promising efficacy and acceptable toxicity 
delivering 65 Gy in 26 fractions of 2.5 Gy to the prostate bed.  The 4-year actuarial PFS 
rate was 67.0% with a median overall follow-up of 32.4 months (range, 5.8-70.5) [Kruser 

NRG-GU003 
13  
Version Date: April 26, 2019   
2011]. And, in a subset analysis of the first 50 patients, with a longer median follow-up 
of 43 months, actuarial 5-year PFS was also 67.0%.  Acute grade 2 or greater GU 
toxicities were noted in 8 (7%) patients.  And at last follow-up, only 3 (3%) patients had 
grade 2 late GU toxicity.  Acute grade 3 GU toxicity (obstruction) was noted in only one 
patient with previous bladder neck contracture.  No acute grade 4 or late grade ≥ 3 
urinary toxicities were documented.  Acute grade 2 gastrointestinal (GI) toxicities 
occurred in 15 (14%) patients, consisting of rectal pain requiring medication (n = 4), 
diarrhea requiring medication (n = 6), and/or bleeding or hemorrhoid exacerbation (n = 
6). No acute grade ≥ 3 GI toxicities were noted.  Late grade 2 GI toxicities were noted in 
4 (4%) patients, all consisting of radiation proctitis. Two of these patients had endoscopic 
cautery to treat rectal bleeding.  At the time of last follow-up, one patient had grade 2 late 
GI toxicity.  No late grade ≥ 3 GI toxicities were documented. 
2.2.6 Dose-escalated Hypofractionation 
The traditional method for equating doses delivered in varying fractionation employs the 
linear-quadratic equation that can calculate a biologic equivalent dose (BED) and derive 
an iso-effective dose in 2 Gy fractions (EQD2) assuming an α/β for the tissue of interest.  
The α/β is a measure of the sensitivity to fraction size and lower values are less sensitive.  
Tissues with a small α/β ratio (i.e., 2 – 4 Gy) are more sensitive to changes in 
fractionation than tissue with a large α/β ratio (i.e., >8 Gy). 
 
Table 1 shows the EQD2 values for the University of Wisconsin experience assuming an 
α/β of 1.5 Gy for prostate (Leborgne 2012, Vogelius 2013, Proust-Lima 2011, Dasu 
2007, Dasu 2012)  and 5 Gy for rectum (Brenner 2004). The α/β for bladder is not as well 
defined and may range from 3 to 10 Gy (Hall 2012, van der Kogel 2009). An α/β for 
bladder for the purpose of this trial is conservatively assumed to be 3 Gy.  The low 
toxicity observed with this fractionation schedule (see Section 2.2.5) is in agreement with 
the reports of acceptable toxicity with EQD2 escalation ≥ 70 Gy in conventional 
fractionation (De Meerleer 2008, Wiegel 2009, Van Der Poel 2008, Feng 2007, Hunter 
2012, Goenka 2012).  
 
Table 1: EQD2 values for COPORT and α/β values for prostate, bladder, and 
rectum  
D (Gy) 
d 
(Gy) 
α/β (Gy) 
EQD2 (Gy) 
75 
2.5 
1.5 (prostate 
cancer) 
74 
75 
2.5 
3 (bladder) 
72 
75 
2.5 
5 (rectum) 
70 
Abbreviations: COPORT = conventionally fractionated post-prostatectomy 
radiotherapy; D = total dose; d = fraction size; EQD2 = equivalent dose in 2 
Gy fractions 
 
 
2.2.7 Selection of RT Doses for COPORT and HYPORT 
COPORT, ARM I, 66.6 Gy in 37 fractions of 1.8 Gy over approximately 7.4 weeks  
Adjuvant RT Dose:  The three randomized trials supporting adjuvant post-prostatectomy 

NRG-GU003 
14  
Version Date: April 26, 2019   
RT used a range of doses from 60 - 64 Gy in 2 Gy fractions (Thompson 2006, Bolla 
2005, Wiegel 2009). 
 
Standard Fraction Size:  A fraction size of 1.8 Gy is preferred for ARM I because the 
NRG Oncology standard for conventional fractionation is 1.8 Gy with which the 
RTOG/NRG Oncology has enjoyed great success in trial completion.  The reported post-
prostatectomy trial RTOG 9601 (Shipley 2010) and not yet reported RTOG 0534 
(NCT00567580) have used 1.8 Gy per fraction.  It is unknown if there will be similar 
success with a fractions size of 2 Gy.  Therefore, the conventional arm of the proposed 
trial will be consistent with other NRG Oncology/RTOG legacy trials, which is based on 
1.8 Gy fractions.   
 
Equivalent Dose Calculation For COPORT:  Table 2 shows the EQD2 values for 
COPORT. The 66.6 Gy dose is preferred for COPORT because: 1) the EQD2 for prostate 
cancer falls within the ranges of doses used the randomized trials of adjuvant RT 
(Thompson 2006, Bolla 2005, Wiegel 2009), 2) it is in agreement with patterns of 
salvage RT that will also be used in the trial (Stephenson 2007), and 3) it was preferred 
by the NRG Oncology GU steering committee. 
 
Table 2: EQD2 values for COPORT and α/β values for prostate, bladder, and 
rectum  
D (Gy) 
d 
(Gy) 
α/β (Gy) 
EQD2 (Gy) 
66.6 
1.8 
1.5 (prostate 
cancer) 
63 
66.6 
1.8 
3 (bladder) 
64 
66.6 
1.8 
5 (rectum) 
65 
Abbreviations: COPORT = conventionally fractionated post-prostatectomy 
radiotherapy; D = total dose; d = fraction size; EQD2 = equivalent dose in 2 
Gy fractions 
 
HYPORT, ARM II, 62.5 Gy in 25 fractions of 2.5 Gy over 5 weeks   
A 2.5 Gy fraction size is preferred for HYPORT because: 1) it is identical to the 
fraction size used in the University of Wisconsin prostate bed hypofractionation 
Phase II trial that provides preliminary toxicity and efficacy data (Kruser 2011), 2) it 
is identical to the fraction size used in the hypofractionated arm of the randomized 
trial RTOG 0415 (NCT00331773) that provides EPIC results for the Phase II sample 
size calculation, and 3) it is in line with the fraction sizes used by the Cleveland 
Clinic (Kupelian 2007, Kupelian 2005) and Fox Chase (Pollack 2011, Pollack 2006).  
 
Equivalent Dose Calculation For HYPORT: The trial is designed such that the 
HYPORT dose represents an 8 Gy dose escalation compared to COPORT.  HYPORT 
is designed to deliver an EQD2 for prostate cancer of 71 Gy (i.e. 63 Gy + 8 Gy), 
which is equivalent to 62.5 Gy in 2.5 Gy fractions.  Table 3 shows EQD2 values for 
the prostate, rectum, and bladder with HYPORT. 

NRG-GU003 
15  
Version Date: April 26, 2019   
 
 
 
Table 3: EQD2values for HYPORT and α/β values for prostate, bladder, and 
rectum 
D (Gy) 
d 
(Gy) 
α/β (Gy) 
EQD2 (Gy) 
62.5 
2.5 
1.5 (prostate 
cancer) 
71 
62.5 
2.5 
3 (bladder) 
69 
62.5 
2.5 
5 (rectum) 
67 
Abbreviations: HYPORT = hypofractionated post-prostatectomy radiotherapy; 
D = total dose; d = fraction size; EQD2= equivalent dose in 2 Gy fractions 
 
While there is dose escalation hypothesized for the rectum and bladder with 
HYPORT compared to COPORT, radiobiologically equivalent rectal and bladder 
treatment planning dose constraints will be used to safeguard against the risk of 
greater rectal and/or bladder toxicity with HYPORT related to dose escalation. 
 
2.3 
This trial is important because:  
• It is the only Phase III trial in the world exploring hypofractionation in the 
postoperative arena. 
• It may redefine the standard of care to include HYPORT. The potential advantages of 
HYPORT are:  
o Increase access for patients to postprostatectomy radiotherapy because of 
fewer treatment days,  
o Increase convenience to patients because of fewer treatment days,  
o Reduced cost to patients because of fewer travel expenses and copays,  
o Improved resource utilization for physicians because fewer number of 
treatments per patient and overall,  
o Reduced cost to society,   
o Increased RT utilization, 
o Improved efficacy of radiation treatment due to biological dose escalation. 
 
3. PATIENT SELECTION, ELIGIBILITY, AND INELIGIBILTY CRITERIA 
 
 
Note: Per NCI guidelines, exceptions to inclusion and exclusion criteria are not 
permitted.  For questions concerning eligibility, please contact the Biostatistical/Data 
Management Center (via the contact list on the NRG web site). For radiation therapy-related 
eligibility questions, please contact RTQA (via the contact list on the NRG web site).  
 
3.1 
Patient Selection Guidelines 
Although the guidelines provided below are not inclusion/exclusion criteria, investigators 

NRG-GU003 
16  
Version Date: April 26, 2019   
should consider these factors when selecting patients for this trial. Investigators also 
should consider all other relevant factors (medical and non-medical), as well as the risks 
and benefits of the study therapy, when deciding if a patient is an appropriate candidate 
for this trial. 
 
3.1.1 Patients must have the psychological ability and general health that permits completion of 
the study requirements and required follow up, including all quality of life surveys 
through 5 years of follow-up. 
 
3.2 
Eligibility Criteria 
A patient cannot be considered eligible for this study unless ALL of the following 
conditions are met. 
 
Prior to Step 1 Registration 
3.2.1 Adenocarcinoma of the prostate treated primarily with radical prostatectomy. 
• Any type of radical prostatectomy will be permitted, including retropubic, perineal, 
laparoscopic or robotically assisted. There is no time limit for the date of radical 
prostatectomy. 
 
3.2.2 One of the following pathologic T-classifications: pT2 or pT3. 
• Patients with positive surgical margins are eligible. 
 
3.2.3    One of the following pathologic N-classifications: pN0, pNX. 
• If  a lymph node dissection is performed, the number of lymph nodes removed per 
side of the pelvis and the extent of the pelvic lymph node dissection (obturator vs. 
extended lymph node dissection) should be noted whenever possible.  
 
3.2.4      No clinical evidence of regional lymph node metastasis. 
• CT (with contrast if renal function is acceptable; a noncontrast CT is permitted if 
the patient is not a candidate for contrast), MRI, nodal sampling, or dissection of 
the pelvis within 120 days prior to Step 1 registration. 
• Patients with pelvic lymph nodes equivocal or questionable by imaging are 
eligible if the nodes are ≤ 1 cm in the short axis. 
 
3.2.5 A post-radical prostatectomy study entry PSA ≥45 days after prostatectomy and within 
30 days prior to Step 1,  < 2.0 ng/mL.  
3.2.6 No evidence of a local recurrence in the prostate fossa based on a digital rectal 
examination (DRE)  within 60 days prior to Step 1 registration. 
• Patients with equivocal or questionable DRE findings should have an MRI of the 
pelvis to exclude the presence of a prostate fossa mass. 
• Patients with equivocal or questionable exam findings by DRE or MRI are 
eligible if a biopsy of the lesion is negative for tumor. 
3.2.7 No evidence of bone metastases (M0) on bone scan (Na F PET/CT is an acceptable 
substitute) within 120 days prior to Step 1 registration.  
• Equivocal bone scan findings are allowed if plain films and/or MRI are negative 
for metastasis. 

NRG-GU003 
17  
Version Date: April 26, 2019   
  
3.2.8 Zubrod Performance Status 0-1 within 60 days prior to Step 1 registration. 
3.2.9 Age ≥ 18 
3.2.10 The patient or a legally authorized representative must provide study-specific informed 
consent prior to Step 1 registration. 
3.2.11  Willingness and ability to complete the Expanded Prostate Cancer Index Composite (EPIC) 
questionnaire (see Section 11.2.1).  
3.2.12 Only English and French-speaking patients are eligible to participate as these are the only 
language the EPIC has been validated in. 
 
Prior to Step 2 Registration 
3.2.13  The EPIC must be completed in full and entered within 10 business days after Step 1 
registration.  NRG Oncology Statistical and Data Management Center has 3 business 
days to score the results and send a notification to the site to proceed to Step 2 
Randomization.   
 
 
3.3 
Ineligibility Criteria 
Patients with any of the following conditions are NOT eligible for this study. 
 
3.3.1 A post-prostatectomy PSA nadir ≥ 0.2 ng/mL AND Gleason ≥ 7 (Considered for NRG-
GU002, PI: Hurwitz).   
3.3.2     pT2 with a negative surgical margin and PSA < 0.1 ng/mL 
3.3.3 Androgen deprivation therapy started prior to prostatectomy for > 6 months (180 days) 
duration. Note: The use of finasteride or dutasteride (±tamsulosin) for longer periods 
prior to prostatectomy is acceptable. 
3.3.4  Androgen deprivation therapy started after prostatectomy and prior to Step 1 registration  
for  > 6 weeks (42 days).  
3.3.5  Neoadjuvant chemotherapy before or after prostatectomy. 
3.3.6 Prior invasive (except non-melanoma skin cancer) malignancy unless disease-free for a 
minimum of 3 years and not in the pelvis.  (For example, carcinoma in situ of the oral 
cavity is permissible if disease free for a minimum of 3 years; however, patients with 
prior history of bladder cancer are not allowed no matter the disease free duration).  Prior 
hematological (e.g., leukemia, lymphoma, myeloma) malignancy is not allowed. 
3.3.7 Previous chemotherapy for any other disease site if given within 3 years prior to Step 1 
(see Section 3.3.6).  
3.3.8 Prior radiotherapy, including brachytherapy, to the region of the study cancer that would 
result in overlap of radiation therapy treatment volumes. 
3.3.9 Severe, active co-morbidity, defined as follows: 
• Unstable angina and/or congestive heart failure requiring hospitalization within the 
last 6 months 
• Transmural myocardial infarction within the last 6 months 
• Acute bacterial or fungal infection requiring intravenous antibiotics at the time of 
Step 1 registration 

NRG-GU003 
18  
Version Date: April 26, 2019   
• Chronic obstructive pulmonary disease exacerbation or other respiratory illness 
requiring hospitalization or precluding study therapy at the time of Step 1 
registration 
• Severe hepatic disease, defined as a diagnosis of Child-Pugh Class B or C hepatic 
disease 
• HIV positive with CD4 count < 200 cells/microliter. Note that patients who are 
HIV positive are eligible, provided they are under treatment with highly active 
antiretroviral therapy (HAART) and have a CD4 count ≥ 200 cells/microliter within 
30 days prior to registration. Note also that HIV testing is not required for eligibility 
for this protocol. 
• End-stage renal disease (ie, on dialysis or dialysis has been recommended) 
3.3.10 Prior allergic reaction to the study drugs involved in this protocol 
3.3.11 History of inflammatory bowel disease, prior bowel surgeries (or colostomy) for any 
reason, or prior partial/radical cystectomy for any reason 
 
 
4. REQUIREMENTS FOR STUDY ENTRY, TREATMENT, AND FOLLOW-UP  
(26-APR-2019) 
 
PRE-TREATMENT ASSESSMENTS 
Assessments 
Time Point (may be required for eligibility) 
 
No more than 120 
days prior to Step 1 
registration 
No more than 90 
days prior to Step 1 
registration 
No more than 60 
days prior to Step 
1 registration 
No more than 30 
days prior to Step 
1 registration 
History & Physical with 
DRE and Zubrod 
Performance Status 
(required) 
 
 
X 
 
Serum PSA (required) 
 
 
 
X 
CT/MRI (Pelvic +/- 
Abdominal) 
X 
 
 
 
Bone scan (required) (see 
Section 3.2.7) 
X 
 
 
 
EPIC (required) 
Completed and submitted prior to Step 2 registration 
EQ-5D  
Completed and submitted prior to Step 2 registration 
Whole blood, serum, 
plasma, & urine (if patient 
consents, see section 10) 
Pre-radiation therapy 
 

NRG-GU003 
19  
Version Date: April 26, 2019   
 
ASSESSMENTS DURING TREATMENT (radiotherapy) 
 
         Assessment                        Time Point 
 
Assessment 
Weekly 
Last Week 
 
 History & Physical and 
AE evaluation  
 
X 
 
Serum, plasma, and 
urine (if patient consents) 
See Section 10 
 
 
X 
 
 
 
ASSESSMENTS IN FOLLOW UP ARE TO BE SCHEDULED FROM THE START OF 
RADIATION STARTING FROM 6 MONTHS 
 
 
Assessment 
End of 
RT 
q 6 
months 
during yrs 
1-2 
1 year  
2 year  
q 12 
months 
during 
yrs 3-5 
5 years  
Yearly 
after 5 
yrs  
Physical 
exam with 
DRE 
 
 
X 
 
 
X 
 
X 
Serum PSA 
X 
X 
 
 
X 
 
X 
AE 
evaluation 
X 
X 
 
 
X 
 
X 
EPIC 
(required) 
X 
X (only at 
6 months) 
X 
X 
 
X 
 
EQ-5D 
 
X 
X (only at 
6 months) 
X 
X 
 
X 
 
Serum & 
plasma (if 
patient consents) 
 
 
X  
 
 
 
 
 
Definition of Disease Assessments 
• Biochemical failure: Two definitions of biochemical failure will be assessed: 
o Primary: PSA ≥ 0.4 ng/mL and rising (i.e. PSA ≥ 0.4 ng/mL followed by a value 
higher than the first by any amount) or initiation of salvage hormones. 
o Alternate: PSA ≥ PSA nadir + 2 ng/mL where nadir is the lowest post-RT PSA 
level. 
• Local failure: development of a new biopsy-proven mass in the prostate bed,  after 
enrollment in the protocol. 

NRG-GU003 
20  
Version Date: April 26, 2019   
• Regional failure: radiographic evidence (CT or MRI) of lymphadenopathy (lymph node 
size ≥ 1.0 cm in the short axis) in a patient without the diagnosis of a 
hematologic/lymphomatous disorder associated with adenopathy. 
• Distant metastases: radiographic evidence of hematogenous spread (e.g., bone scan, CT, 
MRI) 
• Progression: first occurrence of biochemical failure, local failure, regional failure, distant 
metastasis, initiation of new unplanned anticancer treatment, or death from prostate 
cancer. 
 
 
5. TREATMENT PLAN/REGIMEN DESCRIPTION 
 
5.1 
Chemotherapy/Hormonal Therapy/Other Agent-Based Therapy  
For patients receiving RT + androgen deprivation therapy (ADT), ADT may begin at any 
time following Step I registration but prior to the start of RT.  ADT prior to Step I 
registration is allowed but, patient  may have received prior ADT for up to 6 weeks (42 
days) prior to Step 1 registration.  
 
5.1.1 Androgen Deprivation Therapy (ADT) 
Any LHRH agonist/antagomist with or without an oral antiandrogen can be used; 
however, ADT cannot be administered for more than a 6 month administration dose (i.e. 
for Lupron this would be 45 mg, etc.). An oral antiandrogen alone cannot be used.  
The total administered duration as well as the specific agent (s) used will be submitted on 
the appropriate case report form. 
 
 
 
5.2 
Radiation Therapy (26-APR-2019) 
 
Start of Radiotherapy (RT) 
For patients receiving RT alone (no androgen deprivation therapy [ADT]), RT must begin 
within 4 weeks after Step 1 registration. For patients receiving RT+ADT, RT must begin 
8 weeks  (plus or minus 1 week) after the first LHRH analog injection.  Patient may have 
received prior ADT up to 6 weeks (42 days) prior to Step 1 registration. 
 
Radiation Therapy Schema  
Schema at the beginning of the protocol should be followed. 
 
5.2.1 Treatment Technology 
Photon energies ranging from 60Co to <18 MV are recommended. The following 
techniques such as 3D CRT, IMRT, VMAT, Viewray, Cyberknife or Tomotherapy are 
allowed. 
 
5.2.2 Immobilization and Simulation 
 
 
Immobilization 
Proper immobilization is critical for this protocol.  Patient setup reproducibility must be achieved 

NRG-GU003 
21  
Version Date: April 26, 2019   
using appropriate clinical devices. 
 
Immobilization of the hips and feet using a cradle should be considered. Each patient will be 
positioned in the supine position.  Prone positioning for treatment is not permitted.  
 
 
Simulation  
Rectal Filling - An overly distended rectum can introduce a systematic positioning error that 
may increase the probability of missing the clinical target volume (CTV).  Patients should be 
simulated with the rectum as empty as possible and <3 cm in the anterior-posterior dimension is 
ideal. This can be achieved with an enema 1-2 hours prior to simulation.  If the size of the rectum 
is large due to flatus, a hollow (robnel) catheter introduceted into the rectum may be helpful.  
Rectal balloons for planning and treatment are not permitted.   
 
Bladder Filling - Patients should also have a comfortably full bladder (the patient should not be 
uncomfortable at simulation because it is likely that he will have more difficulty maintaining a 
full bladder during treatment).  
 
Identification of the most inferior portion Prostate Fossa - A retrograde urethrogram or MRI 
is recommended, but not required, to establish the most inferior portion of the prostate fossa. 
Note: Use of contrast, other than for the urethrogram, is discouraged.  
 
Image Scanning Parameters - A treatment planning CT scan will be required to define the 
clinical and planning target volumes, and the critical normal structures.  The treatment planning 
CT will be acquired with the patient set up in the same position as for daily treatments.  The CT 
scan of the pelvis should start at or above the iliac crest down to below the perineum (below the 
ischial tuberosities).  All tissues to be irradiated must be included in the CT scan.  CT scan 
thickness should be ≤ 0.3 cm through the region that contains the target volumes.  The regions 
above and below the target volume region may be scanned with slice thickness ≤ 1.0 cm. 
 
 
5.2.3    Imaging for Structure Definition, Image Registration/Fusion and Follow-up 
MRI may be used to assist in volume delineation and precision in all eligible patients. 
However, care should be taken to ensure that the geometric and special orientation of the 
structure set are accurate on the treatment planning CT because CT is used for the dose 
calculation and basis for image guidance.   
 
5.2.4 Definition of Target Volumes and Margins 
Note: All structures must be named for digital RT data submission as listed in the table 
below.  The structures marked as “Required” in the table must be contoured and 
submitted with the treatment plan. Structures marked as “Required when applicable” 
must be contoured and submitted when applicable. 
 
Resubmission of data may be required if labeling of structures does not conform to the standard 
DICOM name listed.  Capital letters, spacing and use of underscores must be applied exactly as 
indicated. 

NRG-GU003 
22  
Version Date: April 26, 2019   
 
 
 
Arm 1 (COPORT) 
 
Standard DICOM 
Name 
Description 
Validation 
 
CTV_6660 
Clinical 
Target 
Volume 
receiving 
66.6 Gy 
Required 
PTV_6660 
Planning 
Target 
Volume 
receiving 
66.6 Gy 
Required 
 
Arm 2 (HYPORT) 
 
Standard DICOM 
Name 
Description 
Validation 
 
CTV_6250 
Clinical Target 
Volume 
receiving 62.5 
Gy 
Required 
PTV_6250 
Planning Target 
Volume 
receiving 62.5 
Gy 
Required 
 
 
Detailed Specifications  
 
CTV and Critical Structure Volumes 
All contouring should be done in accordance with the RTOG consensus recommendations for the 
prostate bed (Michalski 2010) and normal pelvic structures (Gay 2012). The RTOG contouring 
atlas for the prostate bed CTV can be accessed at 
http://www.rtog.org/CoreLab/ContouringAtlases/ProstatePostOp.aspx and for the normal pelvic 
structures at 
http://www.rtog.org/CoreLab/ContouringAtlases/MaleRTOGNormalPelvisAtlas.aspx. 
 
CTV 
The contouring of the prostate bed should be in accordance with the RTOG consensus guidelines 
(Michalski 2010). Briefly, the CTV should extend superiorly from the level of the caudal vas 
deferens remnant to >8-12 mm inferior to vesicourethral anastomosis (VUA). Below the superior 

NRG-GU003 
23  
Version Date: April 26, 2019   
border of the pubic symphysis, the anterior border extends to the posterior aspect of the pubis 
and posteriorly to the rectum, where it may be concave at the level of the VUA. At this level, the 
lateral border extends to the levator ani. Above the pubic symphysis, the anterior border should 
encompass the posterior 1-2 cm of the bladder wall; posteriorly, it is bounded by the mesorectal 
fascia. At this level, the lateral border is the sacrorectogenitopubic fascia. Seminal vesicle 
remnants, if present, should be included in the CTV if there is pathologic evidence of their 
involvement. 
 
PTV 
The PTV margins should be a minimum of 0.7 cm and a maximum of 1.0 cm in all dimensions.  
Plans must be normalized to cover 95% of the PTV with the prescribed dose.  Care should be 
taken to conform the prescribed dose as closely to the PTV as possible, so as to avoid including 
the entire width of the rectum in the posterior blocked margin at the bladder neck-rectum 
interface.   
 
5.2.5 
Definition of Critical Structures and Margins 
Note: All structures must be named for digital RT data submission as listed in the 
table below.  The structures marked as “Required” in the table must be contoured and 
submitted with the treatment plan. Structures marked as “Required when applicable” 
must be contoured and submitted when applicable.   
Resubmission of data may be required if labeling of structures does not conform to 
the standard DICOM name listed.  Capital letters, spacing and use of underscores 
must be applied exactly as indicated. 
 
The normal critical structures are the bladder, rectum, and femoral heads. The normal tissues will 
be contoured and considered as solid organs.  
 
 
 
Bladder 
The bladder should be contoured from its base to the dome, excluding the CTV (the 
CTV includes the bladder neck). 
 
 
 
Rectum 
The rectum should be contoured from the anus (at the level of the ischial tuberosities) 
to the rectosigmoid flexure (this is roughly at about 10 cm) or for a maximum length 
of 15 cm if the sigmoid flexure if felt to be higher. Care should be taken to avoid 
bowel as needed.   
 
 
 
Femoral Heads 
Each femoral head should be outlined down to the interface between the greater and 
lesser trochanters. Each femoral head should be considered separately.  
 
 
 
External 
The tissue within the skin and outside all other critical normal structures and PTV’s is 
designated as unspecified tissue.  
 
 
 
 

NRG-GU003 
24  
Version Date: April 26, 2019   
 
The following table outlines the naming of the various normal and critical structures for 
submission to RTOG via TRIAD. 
 
Standard DICOM 
Name 
Description 
Validation 
 
Bladder 
Bladder 
Required 
Rectum 
Rectum 
Required 
External 
Skin 
Required 
Femur_L 
Left Femur 
Required 
Femur_R 
Right Femur  Required 
Femurs 
Right Femur 
+ Left Femur Required 
 
Detailed Specifications 
5.2.6 
Dose Prescription 
Note: The information provided in this section can be used for adjusting the dose constraints for 
treatment planning purposes.  This table together with the planning priority table should be used 
during dose optimization.  It is important to remember that ideal plans might not be achievable in 
all cases.  Thus, the Compliance Criteria table could be different than the information given here.  
Cases will be scored using the Compliance Criteria table. 
 
Target 
Standard Name 
Dose (Gy) Fraction 
Size (Gy) 
# of 
fractions  
Dose 
specification 
technique 
PTV_6660 
66.60 
1.8 
37 
Covering 95% 
of PTV 
PTV_6250 
62.5 
2.5 
25 
Covering 95% 
of PTV 
 
5.2.7 
Compliance criteria 
The compliance criteria listed here will be used to score each case.  Given the limitations 
inherent in the treatment planning process, the numbers given in this section can be different than 
the prescription table.  The Per Protocol and Variation Acceptable categories are both considered 
to be acceptable.  The Per Protocol cases can be viewed as ideal plans, and the Variation 
Acceptable category can include more challenging plans that do not fall at or near the ideal 
results.  A final category, called Deviation Unacceptable, results when cases do not meet the 
requirements for either Per Protocol or Variation Acceptable. Plans falling in this category are 
considered to be suboptimal and additional treatment planning optimization is recommended. 
 
Normalization of Dose: The plan is normalized such that at least 95% of the PTV_6660 volume 
receives prescription dose of 66.6 Gy for ARM I (COPORT) or at least 95% of the PTV_6250 
volume receives prescription dose of 62.5 Gy for ARM II (HYPORT). 
 
Note: Deviation Unacceptable occurs when dose limits for Variation Acceptable are not 
met 

NRG-GU003 
25  
Version Date: April 26, 2019   
 
 
Target Volume Constraints and Compliance Criteria 
Structure 
Dosimetric 
Parameter 
Per Protocol 
Variation 
Acceptable 
Deviation 
Unacceptable 
PTV 
V100%[%] 
>=95 
>=94 
<94 
PTV maximum 
dose  
D0.03cc[%] 
<=  115 
>115 - <=120 
>120 
PTV minimum 
dose  
D99%[%] 
>= 95 
>=  93 –  < 95  
< 93  
Per Protocol range is excluded from Variation Acceptable range. 
 
Normal Structure Constraints and Compliance Criteria 
The following normal tissue dose constraints represent the minimum level of acceptablibility for 
protocol therapy.  Whever possible, maximal sparing of normal tissues should be achieved to 
minimize the risk of toxicity. 
 
 
Normal Tissue Dose Constraints (ARM I, COPORT) 
 
Structure 
Dosimetric 
Parameter 
Per Protocol 
Variation Acceptable 
Rectum 
V40 Gy[%] 
V65 Gy[%] 
< 55 
< 35 
< 60 
< 39 
Bladder 
V40 Gy[%] 
V65 Gy[%] 
< 70 
< 50 
< 77 
< 55 
Femoral Heads 
V50 Gy[%] 
< 10 
< 11 
 
 
Normal Tissue Dose Constraints (ARM II, HYPORT) 
Structure 
Dosimetric 
Parameter 
Per Protocol 
Variation Acceptable 
Rectum 
V36 Gy[%] 
V59 Gy[%] 
< 55 
< 35 
< 60 
< 39 
Bladder 
V35 Gy[%] 
V57 Gy[%] 
< 70 
< 50 
 
< 77 
< 55 
 
Femoral Heads 
V44 Gy[%] 
< 10 
< 11 
Per Protocol range is excluded from Variation Acceptable range. 
 
 
5.2.8 Treatment Planning Priorities and Instructions 
In order of priority, the following critical structure are listed in order of decreasing 
importance. The following list is given as an example 

NRG-GU003 
26  
Version Date: April 26, 2019   
1. Rectum 
2. Bladder 
3. Femoral Heads 
 
Dose matrix resolution 
Dose grid size should be ≤ 3 mm in all directions. 
 
5.2.9 Patient specific QA 
Any patient-specific QA that needs to be acquired should follow institutional guidelines. 
For IMRT/VMAT plans, patient specific QA is highly recommended. QA is performed 
by delivering the plan onto a phantom and measuring the dose using an ion chamber 
array or other 2D/3D device. Measured dose distribution will be compared to planned 
dose distribution using a Gamma criterion of 3% dose difference and 3 mm distance to 
agreement. The pass rate should be at least 90% measured for the entire plan. 
 
5.2.10 Daily Treatment Localization/IGRT 
Image-guided radiation therapy (IGRT) is radiation therapy using imaging to facilitate 
accuracy and precision throughout its entire process from target and normal tissue 
delineation, to radiation delivery, to adaptation of therapy to anatomic and biological 
changes over time in individual patients. In this section we use the terminology IGRT 
tofocus on image-guidance at the time of radiation delivery to ensure its adherence to the 
planned treatment. 
 
At the start of each fraction, patients should be initially positioned by laser alignment of skin 
surface tattoos.   
 
Daily IGRT is required.  Fiducial marker placement is preferred but not required. Daily fiducial 
based volumetric IGRT is ideal because fiducials aid in the interpretation by radiation therapists. 
If fiducial markers are not present, volumetric IGRT based on soft-tissue alignment needs to be 
performed.  Finally, volumetric 3D IGRT is preferred because bladder and rectal filling can be 
assessed for patient coaching purposes.  Orthogonal 2D kV imaging requires fiducials.   
Electromagnetic transponders or transabdominal ultrasound to identify the VUA may also be 
used for daily IGRT. 
 
Fiducial markers or electromagnetic transponders may be placed at the bilateral vesicourethral 
anatamosis (VUA) and one in the retrovesicle (RV) space under sterile conditions with antibiotic 
prophylaxis consistent with local practice standards.   The three markers or electromagnetic 
transponders should be identified and contoured on the simulation CT and designated right VUA, 
left VUA, and RV according to their relative positions. The appropriate shifts should be made to 
ensure daily registration of the markers or transponders with the position defined by the 
treatment plan. 
 
All image/signal-guidance data should be recorded and archived at the site and available for 
review, if requested. 
 
 

NRG-GU003 
27  
Version Date: April 26, 2019   
 
5.2.11  Case Review  
The Principal Investigator, Mark Buyyounouski, MD and his designee(s)  will perform 
ongoing remote RT Quality Assurance Review after complete data in TRIAD for cases 
enrolled has been received at IROC Philadelphia-RT.  
 
5.3 
General Concomitant Medication and Supportive Care Guidelines 
5.3.1 Permitted Supportive/Ancillary Care and Concomitant Medications 
 
All supportive therapy for optimal medical care will be given during the study period at 
the discretion of the attending physician(s) within the parameters of the protocol and 
documented on each site’s source documents as concomitant medication.  
 Anticonvulsants 
 Antiemetics 
 Anticoagulants 
 Antidiarrheals 
 Analgesics 
 Hematopoietic Growth Factors 
 Herbal products 
 Nutritional supplementation 
 Highly active antiretroviral therapy (HAART) 
 
5.3.2 Prohibited Therapies 
 Care should be taken to avoid therapies that may contribute or exacerbate GI or GU 
toxicity from radiotherapy. 
 
5.3.3 Participation in Other Trials [if applicable] 
Patients are prohibited from participating in any therapeutic intervention trial. 
 
5.4 
Duration of Therapy 
In the absence of treatment delays due to adverse event(s), treatment may continue as 
specified in the above treatment modality sections or until one of the following criteria 
applies: 
 
Disease progression, 
 
Intercurrent illness that prevents further administration of treatment, 
 
Unacceptable adverse event(s), as described in Section 7 
 
Patient decides to withdraw consent for participation in the study, or 
 
General or specific changes in the patient's condition render the patient unacceptable 
for further treatment in the judgment of the investigator. 
 
6. TREATMENT MODIFICATIONS/MANAGEMENT 
Not applicable 
   
 

NRG-GU003 
28  
Version Date: April 26, 2019   
 
7. ADVERSE EVENTS REPORTING REQUIREMENTS 
 
7.1   
Protocol Agents 
 
Not applicable 
 
7.2  
Adverse Events and Serious Adverse Events (26-APR-2019) 
7.2.1 The descriptions and grading scales found in the revised NCI Common Terminology 
Criteria for Adverse Events (CTCAE), version 4.0 will be utilized until March 31, 2018, 
for all AE reporting, CTEP-AERS, and case report forms. CTCAE version 5.0 will be 
utilized for CTEP-AERS reporting beginning April 1, 2018; all study case report forms 
will continue to use CTCAE version 4.0. All appropriate treatment areas should have 
access to a copy of CTCAE versions 4.0 and 5.0, which can be downloaded from the 
CTEP web site  
(https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm)  
 
7.2.2 Definition of an Adverse Event (AE) 
Any untoward medical occurrence associated with the use of a drug in humans, whether 
or not considered drug related.  Therefore, an AE can be any unfavorable and unintended 
sign (including an abnormal laboratory finding), symptom, or disease temporally 
associated with the use of a medicinal (investigational) product, whether or not 
considered related to the medicinal (investigational) product (attribution of unrelated, 
unlikely, possible, probable, or definite). (International Conference on Harmonisation 
[ICH], E2A, E6).  
 
For multi-modality trials, adverse event reporting encompasses all aspects of protocol 
treatment including radiation therapy, surgery, device, and drug. 
 
Due to the risk of intrauterine exposure of a fetus to potentially teratogenic agents, the 
pregnancy of a study participant must be reported via CTEP-AERS in an expedited 
manner. 
 
7.3 
Expedited Reporting of Adverse Events 
All serious adverse events that meet expedited reporting criteria defined in the reporting 
table below will be reported via the CTEP Adverse Event Reporting System, CTEP-
AERS, accessed via the CTEP web site,  
https://eapps-ctep.nci.nih.gov/ctepaers/pages/task?rand=1390853489613 
 
Submitting a report via CTEP-AERS serves as notification to the NRG 
Biostatistical/Data Management Center and satisfies NRG requirements for expedited 
adverse event reporting. 
 
CTEP-AERS provides a radiation therapy-only pathway for events experienced that 
involve radiation therapy only. These events must be reported via the CTEP-AERS 
radiation therapy-only pathway. 
 

NRG-GU003 
29  
Version Date: April 26, 2019   
In the rare event when Internet connectivity is disrupted, a 24-hour notification must be 
made to the NRG Operations Center by phone, 215-574-3191. An electronic report must 
be submitted immediately upon re-establishment of the Internet connection. 
 
7.3.1 Expedited Reporting Methods 
• Per CTEP NCI Guidelines for Adverse Events Reporting Requirements, a CTEP-
AERS 24-hour notification must be submitted with 24 hours of learning of the 
adverse event. 
• Supporting source documentation is requested by NRG as needed to complete 
adverse event review. When submitting supporting source documentation, include the 
protocol number, patient ID number, and CTEP-AERS ticket number on each page, 
and contact the NRG Operations Center (215-574-3191) for source document 
submission information. 
A serious adverse event that meets expedited reporting criteria outlined in the AE Reporting 
Tables but is assessed by the CTEP-AERS as “an action not recommended” must still be 
reported to fulfill NRG safety reporting obligations. Sites must bypass the “NOT recommended” 
assessment; the CTEP-AERS allows submission of all reports regardless of the results of the 
assessment.  
 
7.3.2 Expedited Reporting Requirements for Adverse Events  
 
For Arm 1:  Any Phase Study Utilizing Standard of Care Radiation Therapy1 
FDA REPORTING REQUIREMENTS FOR SERIOUS ADVERSE EVENTS (21 CFR Part 312) 
NOTE:  Investigators MUST immediately report to the sponsor ANY Serious Adverse Events, whether or 
not they are considered related to the investigational agent(s)/intervention (21 CFR 312.64) 
 An adverse event is considered serious if it results in ANY of the following outcomes:   
1) Death 
2) A life-threatening adverse event  
3) An adverse event that results in inpatient hospitalization or prolongation of existing hospitalization 
for ≥ 24 hours  
4) A persistent or significant incapacity or substantial disruption of the ability to conduct normal life 
functions  
5) A congenital anomaly/birth defect.  
6) Important Medical Events (IME) that may not result in death, be life threatening, or require 
hospitalization may be considered serious when, based upon medical judgment, they may jeopardize 
the patient or subject and may require medical or surgical intervention to prevent one of the 
outcomes listed in this definition. (FDA, 21 CFR 312.32; ICH E2A and ICH E6). 
 
ALL SERIOUS adverse events that meet the above criteria MUST be immediately reported to the 
NCI via CTEP-AERS within the timeframes detailed in the table below. 
Attribution 
Grade 4 
Grade 5 
Unexpected 
Expected 
Unexpected 
Expected 

NRG-GU003 
30  
Version Date: April 26, 2019   
Unrelated 
Unlikely 
 
10 day 
10 day 
Possible 
Probable 
Definite 
24-h/5 day 
10 day 
24-h/5 day 
24-h/5 day 
Expedited AE reporting timelines are defined as: 
o “24-Hour; 5 Calendar Days” - The AE must initially be reported via CTEP-AERS within 24 
hours of learning of the AE, followed by a complete expedited report within 5 calendar 
days of the initial 24-hour report. 
o “10 Calendar Days” - A complete expedited report on the AE must be submitted within 10 
calendar days of learning of the AE. 
 
1Serious adverse events that occur more than 30 days after the last administration of investigational 
agent/intervention and have an attribution of possible, probable, or definite require reporting as follows:  
Expedited 24-hour notification followed by complete report within 5 calendar days for: 
• 
Unexpected Grade 4 and all Grade 5 AEs 
 
 
 
For Arm 2: Phase III Study Utilizing Radiation Therapy (including chemoRT studies)1 
FDA REPORTING REQUIREMENTS FOR SERIOUS ADVERSE EVENTS (21 CFR Part 312) 
NOTE:  Investigators MUST immediately report to the sponsor ANY Serious Adverse Events, whether or not they are considered 
related to the investigational agent(s)/intervention (21 CFR 312.64) 
 An adverse event is considered serious if it results in ANY of the following outcomes:   
1) 
Death 
2) 
A life-threatening adverse event  
3) 
An adverse event that results in inpatient hospitalization or prolongation of existing hospitalization for ≥ 24 hours  
4) 
A persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions  
5) 
A congenital anomaly/birth defect.  
6) 
Important Medical Events (IME) that may not result in death, be life threatening, or require hospitalization may be 
considered serious when, based upon medical judgment, they may jeopardize the patient or subject and may require medical 
or surgical intervention to prevent one of the outcomes listed in this definition. (FDA, 21 CFR 312.32; ICH E2A and ICH 
E6). 
ALL SERIOUS adverse events that meet the above criteria MUST be immediately reported to the NCI via CTEP-AERS 
within the timeframes detailed in the table below. 
Hospitalization 
Grade 1 
Timeframes 
Grade 2 
Timeframes 
Grade 3 
Timeframes 
Grade 4 & 5 
Timeframes 
Resulting in 
Hospitalization  
≥ 24 hrs 
Not required 
10 Calendar Days 
24-Hour 5 Calendar Days 
Not resulting in 
Hospitalization  
≥ 24 hrs 
Not required 
10 Calendar Days 

NRG-GU003 
31  
Version Date: April 26, 2019   
Expedited AE reporting timelines are defined as: 
o “24-Hour; 5 Calendar Days” - The AE must initially be reported via CTEP-AERS within 24 hours of learning of 
the AE, followed by a complete expedited report within 5 calendar days of the initial 24-hour report. 
o “10 Calendar Days” - A complete expedited report on the AE must be submitted within 10 calendar days of 
learning of the AE. 
 
1Serious adverse events that occur more than 30 days after the last administration of investigational agent/intervention 
and have an attribution of possible, probable, or definite require reporting as follows:  
Expedited 24-hour notification followed by complete report within 5 calendar days for: 
• 
All Grade 4, and Grade 5 AEs 
Expedited 10 calendar day reports for: 
• 
Grade 3 adverse events 
 
 
Additional Protocol-Specific Instructions or Exceptions to Expedited Reporting 
Requirements: None 
 
7.3.3 Reporting to the Site IRB/REB 
Investigators will report serious adverse events to the local Institutional Review Board 
(IRB) or Research Ethics Board (REB) responsible for oversight of the patient according 
to institutional policy. 
7.3.4 Secondary Malignancy 
A secondary malignancy is a cancer caused by treatment for a previous malignancy (e.g., 
treatment with investigational agent/intervention, radiation or chemotherapy). A 
secondary malignancy is not considered a metastasis of the initial neoplasm.  
 
CTEP requires all secondary malignancies that occur during or subsequent to treatment 
with an agent under an NCI IND/IDE be reported via CTEP-AERS . In addition, 
secondary malignancies following radiation therapy must be reported via CTEP-AERS. 
Three options are available to describe the event: 
• 
Leukemia secondary to oncology chemotherapy (e.g., acute myelocytic leukemia 
[AML])  
• 
Myelodysplastic syndrome (MDS) 
• 
Treatment-related secondary malignancy 
Any malignancy possibly related to cancer treatment (including AML/MDS) should also 
be reported via the routine reporting mechanisms outlined in each protocol.  
 
Second Malignancy:  
A second malignancy is one unrelated to the treatment of a prior malignancy (and is NOT 
a metastasis from the initial malignancy).  Second malignancies require ONLY routine 
reporting via CDUS unless otherwise specified. 
 
 

NRG-GU003 
32  
Version Date: April 26, 2019   
8. REGISTRATION AND STUDY ENTRY PROCEDURES   (26-APR-2019) 
CTEP Registration Procedures and Access requirements for OPEN, Medidata Rave, 
and TRIAD 
Food and Drug Administration (FDA) regulations and National Cancer Institute (NCI) policy 
require all individuals contributing to NCI-sponsored trials to register and to renew their 
registration annually.  To register, all individuals must obtain a Cancer Therapy Evaluation 
Program (CTEP) Identity and Access Management (IAM) account 
(https://ctepcore.nci.nih.gov/iam).  In addition, persons with a registration type of Investigator 
(IVR), Non-Physician Investigator (NPIVR), or Associate Plus (AP) (i.e., clinical site staff 
requiring write access to OPEN, RAVE, or TRIAD or acting as a primary site contact) must 
complete their annual registration using CTEP’s web-based Registration and Credential 
Repository (RCR) (https://ctepcore.nci.nih.gov/rcr).  Documentation requirements per 
registration type are outlined in the table below. 
 
Documentation Required 
IVR 
NPIVR 
AP 
A 
FDA Form 1572 
 
 
Financial Disclosure Form 
 
 
 
NCI Biosketch (education, training, employment, 
license, and certification) 
 
 
 
HSP/GCP training 
 
 
 
Agent Shipment Form (if applicable) 
 
CV (optional) 
 
 
 
 
An active CTEP-IAM user account and appropriate RCR registration is required to access all 
CTEP and CTSU (Cancer Trials Support Unit) websites and applications.  In addition, IVRs 
and NPIVRs must list all clinical practice sites and IRBs covering their practice sites on the 
FDA Form 1572 in RCR to allow the following: 
• Added to a site roster 
• Assigned the treating, credit, consenting, or drug shipment (IVR only) tasks in OPEN 
• Act as the site-protocol PI on the IRB approval 
 
Additional information can be found on the CTEP website at  
< https://ctep.cancer.gov/investigatorResources/default.htm >.  For questions, please contact 
the RCR Help Desk by email at < RCRHelpDesk@nih.gov >. 
 
 
8.1 
Site Registration Requirements (26-APR-2019) 
This study is supported by the NCI Cancer Trials Support Unit (CTSU). 
 

NRG-GU003 
33  
Version Date: April 26, 2019   
IRB Approval  
Each investigator or group of investigators at a clinical site must obtain IRB approval for 
this protocol and submit IRB approval and supporting documentation to the CTSU 
Regulatory Office before they can be approved to enroll patients.  Assignment of site 
registration status in the CTSU Regulatory Support System (RSS) uses extensive data to 
make a determination of whether a site has fulfilled all regulatory criteria including but 
not limited to the following: 
• 
An active Federal Wide Assurance (FWA) number 
• 
An active roster affiliation with the Lead Network or a participating organization 
• 
A valid IRB approval 
• 
Compliance with all protocol specific requirements. 
 
In addition, the site-protocol Principal Investigator (PI) must meet the following criteria: 
• 
Active registration status 
• 
The IRB number of the site IRB of record listed on their Form FDA 1572 
• 
An active status on a participating roster at the registering site. 
Downloading Site Registration Documents:   
Site registration forms may be downloaded from the NRG-GU003 protocol page located 
on the CTSU members’ website.   
• Go to https://www.ctsu.org and log in to the members’ area using your CTEP-
IAM username and password 
• Click on the Protocols tab in the upper left of your screen 
• Either enter the protocol # in the search field at the top of the protocol tree, or 
• Click on the NRG Oncology link to expand, then select trial protocol NRG-
GU003 
• Click on LPO Documents, select the Site Registration documents link, and 
download and complete the forms provided.   
 
Requirements For NRG-GU003 Site Registration: 
• 
IRB approval letter (For sites not participating via the NCI CIRB; local IRB 
documentation, an IRB-signed CTSU IRB Certification Form, Protocol of Human 
Subjects Assurance Identification/IRB Certification/Declaration of Exemption 
Form, or combination is accepted ) 
• IRB/REB Approved Informed Consent (English and native language versions*) 
*Note: Institutions must provide certification/verification of IRB/REB consent 
translation to NRG Headquarters (described below). 
• IRB/REB registration number renewal information as appropriate. 
• CTSU RT Facilities Inventory Form  
NOTE:  Per NCI policy all institutions that participate on protocols with a 
radiation therapy component must participate in the Imaging and Radiation 
Oncology Core (IROC) monitoring program.  If this form has been previously 
submitted to CTSU it does not need to be resubmitted unless updates have 
occurred at the RT facility 
• Credentialing documentation received from IROC Houston for this trial- See 
Section 8.2 Table for details. 
 

NRG-GU003 
34  
Version Date: April 26, 2019   
 
 
Non-English Speaking Canadian and International Institutions: 
*Translation of documents is critical. The institution is responsible for all translation costs. 
All regulatory documents, including the IRB/REB approved consent, must be provided in 
English and in the native language. Certification of the translation is optimal but due to the 
prohibitive costs involved NRG will accept, at a minimum, a verified translation. A verified 
translation consists of the actual REB approved consent document in English and in the 
native language, along with a cover letter on organizational/letterhead stationery that 
includes the professional title, credentials, and signature of the translator as well as signed 
documentation of the review and verification of the translation by a neutral third party. The 
professional title and credentials of the neutral third party translator must be specified as 
well. 
 
Submitting Regulatory Documents:  
Submit required forms and documents to the CTSU Regulatory Office, via the 
Regulatory Submission Portal, where they will be entered and tracked in the CTSU RSS.  
 
Regulatory Submission Portal: www.ctsu.org  (members’ area)  Regulatory Tab 
Regulatory Submission  
When applicable, original documents should be mailed to: 
CTSU Regulatory Office 
1818 Market Street, Suite 3000 
Philadelphia, PA 19103 
 
Institutions with patients waiting that are unable to use the Portal should alert the 
CTSU Regulatory Office immediately at 1-866-651-2878 in order to receive further 
instruction and support. 
 
Checking Your Site’s Registration Status: 
You can verify your site registration status on the members’ section of the CTSU website.   
• Go to https://www.ctsu.org and log in to the members’ area using your CTEP-
IAM username and password 
• Click on the Regulatory tab  
• Click on the Site Registration tab 
• Enter your 5-character CTEP Institution Code and click on Go 
 
Note: The status given only reflects compliance with IRB documentation and institutional 
compliance with protocol-specific requirements outlined by the Lead Network. It does 
not reflect compliance with protocol requirements for individuals participating on the 
protocol or the enrolling investigator’s status with the NCI or their affiliated networks. 
 
8.2 
RT-Specific Pre-Registration Requirements (26-APR-2019) 
For detailed information on the specific technology requirement required for this study, 
please refer to the table below and utilize the web link provided for detailed instructions. 

NRG-GU003 
35  
Version Date: April 26, 2019   
The check marks under the treatment modality columns indicate whether that specific 
credentialing requirement is required for this study. Specific credentialing components 
may require you to work with various QA centers; however, the IROC Houston QA Center 
will notify your institution when all credentialing requirements have been met and the 
institution is RT credentialed to enter patients onto this study. The credentialing 
notification document (email) must be uploaded by the site to the CTSU Regulatory 
Submission Portal for RSS to be updated.   
 
 
8.2.1 Digital RT Data Submission to NRG Using TRIAD 
TRIAD is the image exchange application used by the NRG. TRIAD provides 
sites participating in NRG clinical trials a secure method to transmit DICOM RT 
and other objects.  TRIAD anonymizes and validates the images as they are 
transferred. 
 
TRIAD Access Requirements: 
RT 
Credentialing 
Requirements 
 
Web Link for Credentialing Procedures and Instructions http://irochouston.mdanderson.org 
Treatment Modality 
Photons 
 
Key Information 
 
Facility 
Questionnaire 
  
The IROC Houston electronic facility questionnaire (FQ) should be 
completed or updated with the most recent information about your 
institution.  To access this FQ, email irochouston@mdanderson.org 
to receive your FQ link. 
Credentialing 
Status Inquiry 
Form 
 
  
To determine if your institution has completed the requirements 
above, please complete a “Credentialing Status Inquiry Form” found 
under Credentialing on the IROC Houston QA Center website 
(http://irochouston.mdanderson.org). 
 
 
 
Phantom 
Irradiation 
  
An IMRT phantom study provided by the IROC Houston QA Center 
must be successfully completed. Instructions for requesting and 
irradiating the phantom are found on the IROC Houston web site 
(http://irochouston.mdanderson.org). Note that only the most 
sophisticated  treatment modality  needs to be credentialed, e.g., if 
credentialed for IMRT, 3DCRT may be used.  Tomotherapy, 
Cyberknife and Viewray treatment delivery modalities must be 
credentialed individually.  
 
Credentialing Issued to: 
Institution 
 
 
IROC Houston QA Center will notify the site that all desired 
credentialing requirements have been met. The site will need to 
upload a PDF of  approval email from IROC Houston to the CTSU 
Regulatory Portal for RSS to be updated. 

NRG-GU003 
36  
Version Date: April 26, 2019   
• Site physics staff who will submit images through TRIAD will need to be registered 
with The Cancer Therapy Evaluation Program (CTEP) and have a valid and active 
CTEP Identity and Access Management (IAM) account. Please refer to the 
beginning of Section 8 for instructions on how to request a CTEP-IAM account. 
• To submit images, the site physics user must have been assigned the 'TRIAD site 
user' role on the relevant Group or CTSU roster. NRG users should contact your 
site Lead RA to be added to your site roster.  Users from other cooperative groups 
should follow their procedures for assignment of roster roles. 
• RAs are able to submit standard of care imaging through the same method. 
 
TRIAD Installations: 
When a user applies for a CTEP-IAM account with proper user role, he/she 
will need to have the TRIAD application installed on his/her workstation to 
be able to submit images. TRIAD installation documentation can be found on 
the IROC website https://www.irocqa.org/Resources/TRIAD.    
 
This process can be done in parallel to obtaining your CTEP-IAM account 
username and password. 
 
If you have any questions regarding this information, please send an e-mail to the 
TRIAD Support mailbox at TRIAD-Support@acr.org. 
 
8.3 
Patient Enrollment (26-APR-2019) 
Patient registration can occur only after evaluation for eligibility is complete, eligibility 
criteria have been met, and the study site is listed as ‘approved’ in the CTSU RSS.  Patients 
must have signed and dated all applicable consents and authorization forms.   
 
8.3.1 Oncology Patient Enrollment Network (OPEN) 
Patient enrollment will be facilitated using the Oncology Patient Enrollment Network 
(OPEN). OPEN is a web-based registration system available on a 24/7 basis. To access 
OPEN, the site user must have an active CTEP-IAM account (check at < https://eapps-
ctep.nci.nih.gov/iam/index.jsp >) and a 'Registrar' role on either the LPO or participating 
organization roster. All site staff will use OPEN to enroll patients to this study. It is 
integrated with the CTSU Enterprise System for regulatory and roster data and, upon 
enrollment, initializes the patient position in the Rave database. OPEN can be accessed at 
https://open.ctsu.org or from the OPEN tab on the CTSU members’ side of the web site 
https://www.ctsu.org. 
 
Prior to accessing OPEN site staff should verify the following: 
• All eligibility criteria have been met within the protocol stated timeframes. 
• All patients have signed an appropriate consent form and HIPAA 
authorization form (if applicable).  
Note:  The OPEN system will provide the site with a printable confirmation of 
registration and treatment information.   Please print this confirmation for your 
records.  
 

NRG-GU003 
37  
Version Date: April 26, 2019   
Further instructional information is provided on the OPEN tab of the CTSU members’ 
side of the CTSU website at https://www.ctsu.org or at https://open.ctsu.org.  For any 
additional questions contact the CTSU Help Desk at 1-888-823-5923 or 
ctsucontact@westat.com. 
 
In the event that the OPEN system is not accessible, participating sites can contact NRG 
web support for assistance with web registration: websupport@acr.org or call the NRG 
Registration Desk at (215)-574-3191, Monday through Friday, 8:30 a.m. to 5:00 p.m. ET. 
The registrar will ask the site to fax in the eligibility checklist and will need the registering 
individual’s e-mail address and/or return fax number. This information is required to 
assure that mechanisms usually triggered by the OPEN web registration system (e.g. drug 
shipment and confirmation of registration) will occur.  
 
9.0 DRUG INFORMATION  
 
9.1 
Commercial Agents 
 
ADT can be prescribed at the discretion of the treating physician. 
 
10. PATHOLOGY/BIOSPECIMEN    
 
10.1 
Biospecimen Submission Tables (26-APR-2019) 
 
10.1.1 Optional Specimen Submissions 
(Patients must be offered the opportunity to consent to optional specimen collection. If the 
patient consents to participate, the site is required to submit the patient’s specimens as specified 
per protocol. Sites are not permitted to delete the specimen component from the protocol or from 
the sample consent.) 
 
See detailed specimen collection/processing/shipping instructions on the protocol-specific page 
of the CTSU website. 
 
Optional Study Description #1 
1. Tissue, urine, and blood (including serum and plasma) samples will be collected and banked 
for future research studies.  These exploratory studies will include identifying genes or 
proteins, expressed in the tissue, urine, or blood, that may be associated with toxicity 
following hypofractionated or conventionally fractionated post-prostatectomy radiation.  
These studies will include assessment of both baseline and follow-up samples, to determine if 
early post-treatment changes in genes or proteins can predict subsequent toxicity or response. 
2. Specimen collection kits and instructions are available for frozen specimens from 
NRGBB@ucsf.edu. 5 mm punch kits for FFPE specimens are also available upon request.  
3. Forms- Submit with NRG label on them with Study#, Case#, patient initials,  submitting site 
name and NCI number. 
-ST forms are to be included with all submissions.  
-FFPE submissions must also include pathology reports with all PHI redacted except the 
pathology accession number and date of procedure.  
4. Shipping days for Frozen biospecimens: Monday-Wednesday (US Sites). Monday-Tuesday 
(Canada and overseas). Check NRG Oncology broadcasts for holiday shipping information. 
5. Shipping costs- One prepaid label for each case in provided with kits to be used for batch 

NRG-GU003 
38  
Version Date: April 26, 2019   
shipment of frozen specimen shipments. 
 
For kit requests and questions, contact:  
NRG-GU003 
NRG Oncology Biospecimen Bank—San Francisco 
2340 Sutter Street, Room S341 
University of California San Francisco – Box 1800 
San Francisco, CA 94115 
415-476-7864; NRGBB@ucsf.edu  
 
Specimen Type  
Collection Time Points 
 
Collection Information and  
Requirements/Instructions for 
Site 
Shipping 
 
 
Representative H&E 
stained slides of the 
primary tumor from 
prostatectomy  
 
 
Pre-radiation treatment 
H&E stained slides 
Slides can be duplicate cut H&Es, 
they do not have to be the diagnostic 
slides. H&E slides cannot be returned 
to sites. 
 
Slide shipped ambient to 
NRGBB-SF 
A paraffin-embedded 
tissue block of the 
primary tumor from 
prostatectomy or a 5 
mm diameter core of 
tissue, punched from 
the tissue block with a 
punch tool 
Pre-radiation treatment 
 
 
Paraffin-embedded tissue block or 
5mm punch biopsy. Must be same 
block as H&E being submitted.  
Sites with resources to embed the 
punch should do so and submit a 
matching H&E in addition to the 
H&E from the original block 
 
Block or punch shipped 
ambient or with a cold pack 
in warmer weather to 
NRGBB-SF 
 
Plasma- EDTA tube 
 
5-10 mL of 
anticoagulated whole 
blood in EDTA tube #1 
(purple/ lavender top) 
and centrifuge 
 
Pre-radiation treatment 
 
Last week of RT 
 
At 12 months from the start 
of RT 
 
Frozen plasma samples containing 
minimum 0.5 mL per aliquot in 1 
mL cryovials (five) 
 
Plasma sent frozen in batch 
shipments on dry ice via 
overnight carrier to NRGBB-
SF 
Serum- Red top tube 
 
5-10 mL of whole 
blood in 1 red-top tube 
and centrifuge 
Pre-radiation treatment 
 
Last week of RT 
 
At 12 months from the start 
of RT 
 
 
Frozen serum samples containing  
minimum of 0.5 mL per aliquot in 1 
mL cryovials (five) 
Serum sent frozen in batch 
shipments on dry ice via 
overnight carrier to NRG 
BB-SF 
Whole Blood- EDTA 
tube 
 
Whole blood for DNA: 
5-10 mL of 
anticoagulated whole 
blood in EDTA tube #2 
(purple/lavender top) 
and mix 
Pre-radiation treatment 
 
Note: if site misses this 
collection they may collect it 
at any of the other noted 
timepoints instead. 
 
 
 
Frozen whole blood samples 
containing  1-1.5 ml per aliquot in 
1ml cryovials (three to five) 
Whole blood sent frozen in 
batch shipments on dry ice 
via overnight carrier to NRG 
BB-SF 
10-20 mL clean-catch 
urine   
 
Pre-radiation treatment 
 
Last week of RT 
 
 
 
5-10 mL urine aliquots in 1 or 2 
sterile 15 ml polypropylene 
centrifuge tubes.  Store frozen at  
-20° or -80° C. (-20°C storage is only 
advisable for short term storage)  
Urine sent frozen in batch 
shipments on dry ice via 
overnight carrier to NRG 
BB-SF 
 

NRG-GU003 
39  
Version Date: April 26, 2019   
 
11. SPECIAL STUDIES (NON-TISSUE) 
11.1 
The Expanded Prostate Cancer Index Composite (EPIC; required assessment) 
Health Related Quality of Life as measured by the EPIC questionnaire is the primary 
endpoint in this study. Therefore, every randomized, eligible, analyzable patient on the 
study will complete the EPIC. Patients will complete the EPIC per the schedule in 
Section 4.  
11.1.1  The EPIC is a prostate cancer health-related quality of life (HRQOL) patient self-
administered instrument that measures a broad spectrum of urinary, bowel, sexual, and 
hormonal symptoms related to prostate cancer treatments, including prostatectomy, 
radiotherapy, and hormonal therapy (van Andel 2003). Instrument development was 
based on advice from an expert panel and prostate cancer patients, which led to 
expanding the 20-item University of California-Los Angeles Prostate Cancer Index 
(UCLA-PCI) to the 50-item EPIC. Summary and subscale scores were derived by content 
and factor analyses. Test-retest reliability and internal consistency were high for EPIC 
urinary, bowel, sexual, and hormonal domain summary scores (each r ≥ 0.80 and 
Cronbach's alpha ≥ 0.82) and for most domain-specific subscales. Correlations between 
function and bother subscales within domains were high r > 0.60). Correlations between 
different primary domains were consistently lower, indicating that these domains assess 
distinct HRQOL components. The domains were validated separately, and because each 
domain will be used intact, there is no threat to validity.  
 
Response options for each item form a Likert scale with scores transformed linearly to a 
0-100 scale.  Domain scores are also on a 0-100 scale with higher scores representing 
better HRQOL.  Some items have 5 response options while others have 4.  The bowel 
domain contains 14 questions, the urinary domain contains 12 items, the sexual domain 
contains 13 questions, and the hormonal domain contains 11 questions. 
 
11.1.2 EuroQol (EQ-5D) 
The EQ-5D is a 6-item validated utility assessment instrument that takes less than 5 
minutes to complete (van Agt 1994, Conner-Spady 2001, Brooks 1991, Nord 1991). The 
first part consists of 5 items covering 5 dimensions including: mobility, self-care, usual 
activities, pain/discomfort, and anxiety/depression. Each dimension is graded on 5 levels: 
1-no problems, 2-slight problems, 3-moderate problems, 4-severe problems, and 5-unable 
to perform/extreme problems. Health states are defined by the combination of the leveled 
responses to the 5 dimensions, generating 3, 125 health states. The sixth item is a visual 
analogue scale for overall health.  The 5-item index score is transformed into a utility score 
between 0, “Worst health state,” and 1, “Best health state.” The index score can be used in 
a quality adjusted survival analysis depending on the health state(s) of interest (Wu 2002). 
For this study we plan to report the multidimensional utilities for comparative purposes.  
The measured utility values for each patient on this study will be combined with overall 
survival to calculate the “QALY” quality-adjusted life years.  This will then be used for 
cost-effectiveness analysis comparing the two arms in this trial. Patients will complete the 
EQ-5D as specified in the Study Parameter Table in Section 4. 
 
 
 

NRG-GU003 
40  
Version Date: April 26, 2019   
12.             MODALITY REVIEWS 
12.1 
Radiation Therapy Quality Assurance Reviews(26-APR-2019) 
The Principal Investigator, Mark Buyyounouski, M.D. and his designee(s), will perform a 
RT Quality Assurance Review after IROC Philadelphia-RT has received complete data in 
TRIAD for the cases enrolled. The reviews will be completed remotely and will be ongoing. 
The final cases will be reviewed within 3 months after this study has reached the target 
accrual or as soon as IROC Philadelphia-RT has received complete data in TRIAD for all 
cases enrolled, whichever occurs first. The scoring mechanism is: Per Protocol, 
Acceptable Variation, and Unacceptable Deviation. 
 
13.       DATA AND RECORDS 
13.1 
Data Management/Collection (26-APR-2019) 
Data collection for this study will be done exclusively through Medidata Rave®. Access 
to the trial in Rave is granted through the iMedidata application to all persons with the 
appropriate roles in RSS (Regulatory Support System). To access iMedidata/Rave, the 
site user must have an active CTEP-IAM account and the appropriate Rave role (Rave 
CRA, Rave Read-Only, Rave CRA (Lab Admin), Rave SLA or Rave Investigator) on 
either the LPO or participating organization rosters at the enrolling site. To the hold Rave 
CRA role or Rave CRA (Lab Admin) role, the user must hold a minimum of an AP 
registration type. To hold the Rave Investigator role, the individual must be registered as 
an NPIVR or IVR. Associates can hold read-only roles in Rave. 
 
Upon initial site registration approval for the study in RSS, all persons with Rave roles 
assigned on the appropriate roster will be sent a study invitation e-mail from iMedidata 
(iMedidata-Notification@mdsol.com) to activate their account. To accept the invitation, 
site users must log into the Select Login (https://login.imedidata.com/selectlogin) using 
their CTEP-IAM user name and password, and click on the “accept” link in the upper 
right-corner of the iMedidata page. Please note, site users will not be able to access the 
study in Rave until all required Medidata and study specific trainings are completed. 
Trainings will be in the form of electronic learnings (eLearnings) and will be listed in the 
upper right pane of the iMedidata screen. 
  
Users that have not previously activated their iMedidata/Rave accounts also will receive a 
separate invitation from iMedidata to activate their account. Account activation 
instructions are located on the CTSU website, Rave tab under the Rave resource materials 
(Medidata Account Activation and Study Invitation Acceptance). Additional information 
on iMedidata/Rave is available on the CTSU website under the Rave tab at 
www.ctsu.org/RAVE/ or by contacting the CTSU Help Desk at 1-888-823-5923 or by e-
mail at ctsucontact@westat.com. 
13.2 
Summary of Data Submission 
Adverse event data collection and reporting, which are required as part of every clinical 
trial, are done to ensure the safety of patients enrolled in the studies as well as those who 
will enroll in future studies using similar agents. Adverse events are reported in a routine 
manner at scheduled times during the trial using Medidata Rave®. Additionally, certain 
adverse events must be reported in an expedited manner for more timely monitoring of 
patient safety and care. See Section 7.3 for information about expedited and routine 
reporting.   

NRG-GU003 
41  
Version Date: April 26, 2019   
 
Summary of Data Submission: Refer to the CTSU website.  
 
See Section 8 for TRIAD account access and installation instructions. 
 
13.3 
Global Reporting/Monitoring 
This study will be monitored by the Clinical Data Update System (CDUS) version 3.0. 
Cumulative protocol- and patient-specific CDUS data will be submitted electronically to 
CTEP on a quarterly basis by FTP burst of data. Reports are due January 31, April 30, 
July 31, and October 31. Instructions for submitting data using the CDUS can be found 
on the CTEP Web site (http://ctep.cancer.gov/reporting/cdus.html). 
 
Note: If your study has been assigned to CDUS-Complete reporting, all adverse events 
(both routine and expedited) that have occurred on the study and meet the mandatory 
CDUS reporting guidelines must be reported via the monitoring method identified above.  
If your study has been assigned to CDUS-Abbreviated reporting, no adverse event 
reporting (routine or expedited) is required to be reported via CDUS, but expedited 
adverse events are still required to be submitted via CTEP-AERS. 
 
14. STATISTICAL CONSIDERATIONS 
 
14.1     Study Design 
This is a randomized phase III non-inferiority trial comparing hypofractionated post-
prostatectomy radiation therapy (HYPORT) and conventional post-prostatectomy radiation 
therapy (COPORT).  Patients will be stratified according to baseline EPIC bowel and 
urinary domain scores (high bowel score and high urinary score vs. high bowel score and 
low urinary score vs. low bowel score and high urinary score vs. low bowel score and low 
urinary score) and androgen deprivation therapy (ADT; yes vs. no) then randomized 1:1 to 
receive HYPORT or COPORT according to the permuted block design by Zelen (1974). 
Combination RT and ADT has been associated with increased risks of GI toxicity 
(Feigenberg 2005, Roach 2003) and GU toxicity (Lawton 2008) that may confound the 
primary endpoint. A high bowel score > 96, low bowel score ≤ 96, high urinary score > 
84, and low urinary score ≤84. Determination of high vs. low bowel and urinary scores 
was from baseline scores on RTOG 0534. This is an intent-to-treat analysis and all 
randomized patients will be included in the primary analysis. 
 
 
14.2 
Study Endpoints (26-APR-2019) 
 
14.2.1 Co-primary endpoints: 
1. Two-year change score from baseline for the GI domain of the Expanded Prostate 
Cancer Index (EPIC).  
2. Two-year change score from baseline for the GU domain of the EPIC.  
14.2.2 Secondary endpoints 
1. Patient-reported gastrointestinal (GI) symptoms using the EPIC at the end of RT, 6 
months, 1 and 5 years. 

NRG-GU003 
42  
Version Date: April 26, 2019   
2. Patient-reported genitourinary (GU) symptoms using the EPIC at the end of RT, 6 
months, 1 and 5 years. 
3. Freedom from biochemical failure (FBF)  
4. Time to progression (TTP) where progression is defined as the first occurrence of, BF, 
local failure, regional failure, distant metastasis (DM), institution of new unplanned 
anticancer treatment, or death from prostate cancer (PCSM) 
5. Local failure, regional failure, salvage therapy (i.e. institution of new unplanned 
anticancer treatment), DM, PCSM, and OS rates. 
6. Adverse events using the Common Terminology Criteria for Adverse Events (CTCAE 
v. 4.0). 
 
14.2.3 Exploratory endpoints 
1. Measured utilities for health outcomes using the EQ5D. 
2. Paraffin-embedded tissue block, serum, plasma, whole blood, and urine for future 
translational research analyses for predictors of toxicity following hypofractionated or 
conventionally fractionated post-prostatectomy radiotherapy.   
 
14.3 
Primary Objectives Study Design  
 
 
14.3.1 Primary Hypothesis and Endpoints 
 
1. Hypofractionated postprostatectomy radiotherapy (HYPORT) delivering 62.5 Gy in 
25 fractions of 2.5 Gy to the prostate bed is not associated with excess patient-
reported GI symptoms, as measured by the EPIC bowel domain, compared to 
conventionally fractionated postprostatectomy radiotherapy (COPORT) delivering 
66.6 Gy in 37 fractions of 1.8 Gy to the prostate bed. 
2. HYPORT delivering 62.5 Gy in 25 fractions of 2.5 Gy to the prostate bed is not 
associated with excess patient-reported GU symptoms, as measured by the EPIC 
urinary domain, compared to COPORT delivering 66.6 Gy in 37 fractions of 1.8 Gy 
to the prostate bed. 
14.3.2 How Primary Endpoints Will Be Analyzed  
Analysis of the Primary Endpoints 
The co-primary endpoints are GI and GU toxicity as measured by the bowel and urinary 
EPIC domains, respectively. The change scores, calculated as baseline score subtracted 
from 2-year score, will be analyzed using a t-test with a significance level of 0.025.  If the 
data are determined to be non-normal, a Wilcoxon test may be used instead. Missing data 
will be assessed and is described in more detail in Section 14.6.2. All patients will EPIC 
bowel and urinary domain scores will be included in the primary endpoint analysis.  The 
EPIC scoring manual will be followed which requires ≥ 80% of items in a domain to be 
completed in order to obtain a score for that domain. 
14.3.3 Sample Size and Power Calculations:  
The primary goal of this phase III study is to determine if HYPORT does not increase GI 
and GU toxicity over COPORT.  The primary endpoint is based on change scores from 
the bowel (GI) and urinary (GU) domains of the EPIC. The change scores will be based 
on the 2-year score minus the pretreatment (baseline) score. The hypothesis for this 
endpoint is that the EPIC mean change score is no worse in the HYPORT than it is in the 

NRG-GU003 
43  
Version Date: April 26, 2019   
COPORT arm for either type of toxicity. Section 11.1.2 contains more information about 
the EPIC, such as validation information, number of questions, possible responses, and 
ranges of the scores. 
 
RTOG 0534 has a similar population to this study, however it did not collect EPIC scores 
at 2 years.  Therefore, data from the conventionally-fractionated arm of RTOG 0415 was 
used to aid in calculation the sample size for this study.  To verify that RTOG 0415 data is 
similar to the patient population in this study, EPIC data from the conventionally-
fractionated arm of RTOG 0415 was compared to the results of a recent paper where 
conventionally-fractionated post-prostatectomy patients were surveyed with the EPIC 
questionnaire as to their quality of life (Pinkawa 2008). Pretreatment and 1-year results 
were compared.  For the post-prostatectomy paper, the reported pretreatment and 1-year, 
respectively, mean bowel function scores are 92 and 91, respectively, while for the RTOG 
0415 control arm, the mean bowel function scores at the corresponding time points are 93.0 
and 90.2, respectively.  For post-prostatectomy, the pretreatment and 1-year mean bowel 
bother scores are 94 and 90, respectively, while for RTOG 0415 control, the corresponding 
time point scores are 94.1 and 89.5, respectively.   
 
From the conventional arm of RTOG 0415, in an analysis of 170 eligible patients with the 
bowel domain completed at both baseline and 2 years from the start of RT, the mean change 
(2-years minus baseline) in EPIC bowel domain score was -4.3 points (SE=13.2).  In a 
similar analysis of 173 eligible patients with the urinary domain completed at both baseline 
and 2 years, the mean EPIC urinary domain change score was 0.42 (SE=10.5). 
 
Based on these results an EPIC bowel domain mean change-score of -4 will be 
hypothesized for the COPORT arm, with a non-inferiority margin of 6 for the HYPORT 
arm corresponding to a bowel domain change score at 2 years of -10 in the HYPORT arm. 
An EPIC urinary domain score of 0.4 is hypothesized for the COPORT arm, with a non-
inferiority margin of 5 for the HYPORT arm corresponding to a urinary domain change 
score at 2 years of -4.6 in the HYPORT arm.  So, if the mean bowel or urinary domain 
change score for the HYPORT arm is no more than 6 points worse for bowel or 5 points 
worse for urinary than the mean change score for the COPORT arm, then the HYPORT 
arm will be considered non-inferior.  For the primary endpoint, the null hypothesis (H0) of 
this test is that the mean change score of HYPORT (∆2) is worse than the mean change 
score of COPORT (∆1).  The alternative hypothesis (HA) is that the mean change score of 
HYPORT is not worse than the mean change score of COPORT. 
 
The non-inferiority margin is based on 0.5*SE from the RTOG 0415 analysis due to 
0.5*SD being the cutoff for clinical difference (Barry 1999).  To put the non-inferiority 
margins in context, a change score of 6 points corresponds to two symptoms worsening by 
1 level (i.e. loose stools and frequency of bowel movements change from “no problem” to 
“very small problem”) or one of the symptoms worsening by 2 levels (i.e. loose stool 
change from “no problem” to “small problem”).   
 
The study sample size is based on 90% power for GI endpoint and 91% power for the GU 
endpoint (resulting in 81.9% statistical power to reject the null hypothesis for both 

NRG-GU003 
44  
Version Date: April 26, 2019   
endpoints) and a one-sided alpha=0.025 with an overall type I error of 0.05 with a 
Bonferroni adjustment.  With these design parameters, the sample size is 198 patients. 
Adjusting for a projected 30% EPIC/non-compliance rate, the required sample size is 282 
patients (141 per arm). 
 
 
14.4 
Study Monitoring of Primary Objectives 
Interim Analysis for the DMC 
The NRG Oncology Data Monitoring Committee (DMC) will review the study twice a 
year with respect to patient accrual and morbidity. The DMC also will review the study 
on an “as needed” basis.  
 
Interim Futility Analysis  
There will be a single futility analysis once 50% of patients have 2 years of follow-up.  If 
the upper 95% confidence limit of the mean difference in 2 year change scores between the 
treatment arms is less than the pre-specified non-inferiority margin, then the HYPORT arm 
will be deemed inferior to the COPORT arm.  Specifically, if the upper 95% confidence 
limit of the mean difference between arms in 2 year change scores is < -6 for the bowel 
domain and/or < -5 for the urinary domain, then the HYPORT arm will be deemed inferior 
to the COPORT arm.  Early reporting of the treatment results will be recommended to the 
DMC, who will review these results.  This approach has a minimal effect on statistical 
power. 
 
Monitoring of EPIC Compliance 
Completion rates of the bowel and urinary domains of EPIC will be monitored monthly.  
Since the study is projected to close within 26 months, 2 year data may not be monitored 
while the study is open to accrual.  Therefore, the rates at 6 months and 1 year will be used 
to assess feasibility of the primary endpoint analysis.  If the EPIC non-compliance rate is 
≥ 20% at either of these time points, the study PI and QOL co-chair will work in 
collaboration with the NRG Oncology Statistics and Data Management Center to contact 
sites and RAs with delinquent data, assessments completed too early or too late, and 
assessments not completed due to institution errors.  If the EPIC non-compliance rate is > 
40% at either time point, the study will be presented to the DMC for reassessment of 
feasibility or change in study design. 
 
Interim Analysis to Monitor the Study Progress   
Interim reports with statistical analyses will be prepared twice per year until the initial 
treatment results have been presented/published. In general, the interim reports will 
contain the following information: 
• patient accrual rate with a projected completion date (while the study is still accruing) 
• total patients accrued  
• distributions of important pre-treatment and prognostic baseline variables  
• the frequencies and severity of adverse events by treatment arm 
 
The interim reports will not contain the results from the treatment comparisons with 
respect to the primary and secondary endpoints, with the exception of reporting of 

NRG-GU003 
45  
Version Date: April 26, 2019   
adverse events. 
 
14.5 
Accrual/Study Duration Considerations 
Based on patient accrual in previous RTOG legacy/NRG Oncology studies, the initial 6 
months accrual is projected to be negligible while institutions are obtaining IRB 
approval. This protocol has a similar patient population (post-prostatectomy) to RTOG 
0534.  The accrual rate for the QOL component on that study was 11.3 patients per 
month.  Therefore, the projected accrual rate is 11 patients per month.  Based on this 
information, it is projected that the study will complete accrual in about 26 months from 
the end of the 6-month period of negligibility (32 months from activation). The primary 
endpoint analysis will occur approximately 5 years from study activation. Accrual will be 
monitored in accordance to CTEP accrual guidelines. 
 
14.6 
Secondary Endpoints  
14.6.1 Secondary Hypotheses and Endpoints:  
1. Hypofractionated postprostatectomy radiotherapy (HYPORT) delivering 62.5 Gy in 
25 fractions of 2.5 Gy to the prostate bed is not associated with excess patient-
reported GI symptoms compared to conventionally fractionated postprostatectomy 
radiotherapy (COPORT) delivering 66.6 Gy in 37 fractions of 1.8 Gy to the prostate 
bed at the end of RT, and 6 months, 1 and 5 years from the start of RT. 
2. HYPORT delivering 62.5 Gy in 25 fractions of 2.5 Gy to the prostate bed is not 
associated with excess patient-reported GU symptoms compared to COPORT 
delivering 66.6 Gy in 37 fractions of 1.8 Gy to the prostate bed at the end of RT, and 
6 months, 1 and 5 years from the start of RT. 
3. Comparison of freedom from biochemical failure (FBF) between the HYPORT arm 
and COPORT arm. 
4. Comparison of time to progression (TTP) where progression is defined as the first 
occurrence of, BF, local failure, regional failure, distant metastasis (DM), initiation of 
new unplanned anticancer treatment, or death from prostate cancer (PCSM) between 
the HYPORT arm and COPORT arm. 
5. Comparison of local failure, regional failure, salvage therapy (i.e. initiation of new 
unplanned anticancer treatment), DM, PCSM, and OS rates between the HYPORT arm 
and COPORT arm. 
6. HYPORT is not associated with excess adverse events (AEs) compared to COPORT 
 
 
14.6.2 Definitions of Secondary Endpoints and How These Will Be Analyzed 
Additional EPIC Endpoints 
All four domains of the EPIC will be analyzed, bowel, urinary, sexual, and hormonal.  The 
change scores, calculated as baseline score subtracted from follow-up score, will be 
analyzed using a t-test.  If the data are determined to be non-normal, a Wilcoxon test may 
be used instead. The follow-up timepoints of interest are end of RT, 6 months, 1, 2 (for 
sexual and hormonal domains) and 5 years from the start of treatment. A longitudinal 
analysis incorporating all follow-up time points, will be conducted separately for each 
domain score using a general linear model with maximum likelihood estimation, adjusting 
for baseline domain score, treatment arm, Gleason score, baseline PSA, T-stage, age, and 

NRG-GU003 
46  
Version Date: April 26, 2019   
race. These analyses will be conducted regardless the outcomes of the primary t-test. For 
the comparison of primary endpoints at 2 years adjusting for other variables using the 
longitudinal model, especially stratification variables, the results will be similar to those of 
the primary analysis in general. In the rare case when it is different, we will examine very 
carefully the impact of missing data and the adjusted variables and make a meaningful 
conclusion regarding the outcome.  
 
If any of the domains are found to significantly differ between arms, then analysis of that 
domain’s subscales will be undertaken to assess which particular subscale is driving the 
significant 
difference. 
The 
subscales 
are 
function 
both 
incontinency 
and 
irritative/obstructive for the urinary domain, and function and bother for the bowel, sexual, 
and hormonal domains.  
 
Prior to performing analyses, an evaluation of the amount, reasons and patterns of missing 
data will be performed, using the well-known categories of missing completely at random 
(MCAR), missing at random (MAR) and missing not at random (MNAR) (Fairclough 
2010, Verbeke 2000).  If ≥15% of the data is missing at any time point for the EPIC bowel 
and urinary domain scores, patient characteristics will be compared between patients with 
completed assessments and those with missing assessments. If any are found to differ 
significantly, they will be included in the mixed effects model which assumes that the data 
is MAR.  If the missingness is determined to be non-ignorable, other methods may be 
performed.  Specifically, a joint model that allows a shared parameter between the repeated 
measurements and time to death or drop out can be used if considered MNAR due to the 
high number of patient deaths or dropouts (Rizopoulos 2012).  Other options for MNAR 
data are pattern mixture and selection models (Fairclough 2010, Little 1995).  Sensitivity 
analyses will be performed to compare the results of different analytic strategies 
(Fairclough 1998). 
 
 
Secondary Efficacy Endpoints 
OS is defined as a death from any cause and will be measured from the date of 
randomization to the date of death.  BF is defined as a PSA ≥ 0.4 ng/mL and rising (i.e. 
PSA ≥ 0.4 ng/mL followed by a value higher than the first by any amount) or followed by 
inititation of salvage hormones.  The time of the first occurrence of PSA ≥ 0.4 ng/mL will 
be considered the event time.  An alternative definition of BF will also be assessed: PSA ≥ 
PSA nadir + 2 ng/mL where nadir is the lowest post-RT PSA value.  PCSM will be 
measured from the date of randomization to the date of death due to prostate cancer. LF is 
defined as the development of a new biopsy-proven mass in the prostate bed after 
enrollment in the protocol and will be measured from the date of randomization to the date 
of documented local failure. RF will be defined as radiographic evidence (CT or MRI) of 
lymphadenopathy (lymph node size ≥ 1.0 cm in the short axis) in a patient without the 
diagnosis of a hematologic/lymphomatous disorder associated with adenopathy and will 
be measured from the date of randomization to the date of documented regional metastasis.  
DM is defined as radiographic evidence of hematogenous spread (e.g., bone scan, CT, 
MRI) and will be measured from the date of randomization to the date of documented DM. 
For LF, RF, and DM, a BF is required prior to the LF, RF, and DM but will not be 

NRG-GU003 
47  
Version Date: April 26, 2019   
considered as an event. TTP will be measured from the date of randomization to the date 
of the first occurrence of BF, LF, RF, DM, of PCSM.  Since TTP includes BF as a failure, 
both definitions of BF will be used resulting in two TTP estimates. 
 
Since baseline PSA level is not a stratification factor, hazard ratios and p-values for all 
efficacy endpoints will be analyzed and reported after adjustment for baseline PSA.  
Patients not experiencing an event will be censored at the last known follow-up time. 
Competing-risk endpoints PCSM, LF, RF, TTP, and DM will treat death as a competing 
risk (for PCSM and TTP, any death not due to prostate cancer) and be estimated by the 
cumulative incidence method (Gray 1988). OS and FFBF will be estimated by the Kaplan-
Meier method (Kaplan & Meier 1958) and compared with the log-rank test (Mantel 1966).  
Cox regression (1974) will be used to obtain hazard ratios (HRs) for OS and TTP. Fine and 
Gray’s regression (1999) will be used for the endpoints with competing risks. Adjusted 
HRs and the respective 95% confidence interval will be computed. Baseline PSA, 
stratification variables (baseline EPIC score and ADT status), and, as appropriate, age, 
race, and other covariates (Gleason, T-stage), will be adjusted for in this analysis. Statistical 
power will be limited for these analyses. 
 
Adverse Events 
Adverse events (AEs) will be graded with CTCAE v4.  Counts of all AEs by grade will be 
provided by treatment arm.  Counts and frequencies will be provided for the worst grade 
AE experienced by the patient by treatment arm.  A Chi-square test will be used to compare 
the number of patients with at least 1 grade 3 or higher AE between the treatment arms.  A 
comparison of grade 3 and higher GU and GI events related to treatment (separately) 
between treatment arms will also be tested using a Chi-square test. 
 
 
14.7 
Exploratory Endpoints 
14.7.1  Exploratory Hypotheses and Endpoints 
• Measured utilities and cost-effectiveness for health outcomes using the EQ5D. 
• Paraffin-embedded tissue block, serum, plasma, whole blood, and urine for future 
translational research analyses for predictors of toxicity following hypofractionated or 
conventionally fractionated post-prostatectomy radiotherapy.  Note: Testing of banked 
specimens will not occur until an amendment to this treatment protocol (or separate 
correlative science protocol) is reviewed and approved in accordance with National 
Clinical Trials Network (NCTN) policies. 
 
14.7.2  Definitions of Exploratory Endpoints and How These Will Be Analyzed 
Cost effectiveness 
 
The VAS and index scores from the EQ-5D-5L will be calculated at each time point 
(baseline, end of RT, 6 months, and 1, 2, and 5 years from the start of RT) and compared 
between treatment arms using a t-test  with a 2-sided significance level of 0.05.  If there 
are significant differences, then a cost analysis will be conducted.   
 
Quality-adjusted life years (QALY) is defined by the weighted sum of different time 
episodes added up to a total quality-adjusted survival time.  A Markov model will be used 

NRG-GU003 
48  
Version Date: April 26, 2019   
to model cost for this analysis.  The Medicare reimbursement in dollars/QALY will be 
calculated as a function of the monetary cost per relative value of each health state and its 
duration.  The EQ-5D-5L index score at 6 months and 5 years will be used for the cost-
utility analysis. The z-test will be used to test the hypothesis that the cost-utility in the 
two treatment arms is the same with significance level of 0.05. The cost-utility using the 
Medicare reimbursement in dollars/QALY between the two treatment arms after 
adjusting for the baseline and stratification variables. 
 
 
 
14.8 
Gender/Ethnicity/Race Distribution (26-APR-2019) 
No differences across the patient subsets below are anticipated.   
 
 
 
Racial Categories 
DOMESTIC PLANNED ENROLLMENT REPORT 
Ethnic Categories 
Not Hispanic or 
Latino 
Hispanic or Latino 
 
Total 
Female 
Male 
Female 
Male 
American Indian/Alaska 
Native 
0 
2 
0 
1 
3 
Asian 
0 
2 
0 
0 
2 
Native Hawaiian or Other 
Pacific Islander 
0 
1 
0 
1 
2 
Black or African American 
0 
40 
0 
3 
43 
White  
0 
139 
0 
10 
149 
More Than One Race 
0 
1 
0 
1 
2 
Total 
0 
185 
0 
16 
201 
 
 
 
Racial Categories 
INTERNATIONAL (including Canadian participants) 
PLANNED ENROLLMENT REPORT 
Ethnic Categories 
Not Hispanic or 
Latino 
Hispanic or Latino 
 
Total 
Female 
Male 
Female 
Male 
American Indian/Alaska 
Native 
0 
0 
0 
0 
0 
Asian 
0 
1 
0 
0 
1 
Native Hawaiian or Other 
Pacific Islander 
0 
0 
0 
0 
0 
Black or African American 
0 
2 
0 
0 
2 
White  
0 
70 
0 
8 
78 
More Than One Race 
0 
0 
0 
0 
0 
Total 
0 
73 
0 
8 
81 
 

NRG-GU003 
49  
Version Date: April 26, 2019   
REFERENCES (26-APR-2019) 
 
Anscher, M.S., R. Clough, and R. Dodge, Radiotherapy for a rising prostate-specific antigen 
after radical prostatectomy: the first 10 years. int J Radiat Oncol Biol Phys, 2000. 48(2): 
p. 369-75. 
Arcangeli, G., et al., Acute and late toxicity in a randomized trial of conventional versus 
hypofractionated three-dimensional conformal radiotherapy for prostate cancer. Int J 
Radiat Oncol Biol Phys, 2011. 79(4): p. 1013-21. 
Arcangeli, S., et al., Updated results and patterns of failure in a randomized hypofractionation 
trial for high-risk prostate cancer. int J Radiat Oncol Biol Phys, 2012. 84(5): p. 1172-8. 
Barry, M.J., Quality of life and prostate cancer treatment. J Urol, 1999. 162(2): p. 407. 
Bentzen, S.M., et al., The UK Standardisation of Breast Radiotherapy (START) Trial A of 
radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. 
Lancet Oncol, 2008. 9(4): p. 331-41. 
Bentzen, S.M., et al., The UK Standardisation of Breast Radiotherapy (START) Trial B of 
radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. 
Lancet, 2008. 371(9618): p. 1098-107. 
Bernard, J.R., Jr., et al., Salvage radiotherapy for rising prostate-specific antigen levels after 
radical prostatectomy for prostate cancer: dose-response analysis. int J Radiat Oncol 
Biol Phys, 2010. 76(3): p. 735-40. 
Bolla, M., Adjuvant or Immediate External Irradiation After Radical Prostatectomy with Pelvic 
Lymph Node Dissection for High-Risk Prostate Cancer: A Multidisciplinary Decision. 
Eur Urol, 2012. 
Bolla, M., et al., Postoperative radiotherapy after radical prostatectomy for high-risk prostate 
cancer: long-term results of a randomised controlled trial (EORTC trial 22911). Lancet, 
2012. 380(9858): p. 2018-27. 
 
Bolla, M., et al., Postoperative radiotherapy after radical prostatectomy: a randomised 
controlled trial (EORTC trial 22911). Lancet, 2005. 366(9485): p. 572-8. 
Brenner, D.J., Fractionation and late rectal toxicity. Int J Radiat Oncol Biol Phys, 2004. 60(4): 
p. 1013-5. 
 
Buyyounouski, M.K., et al., Validating the interval to biochemical failure for the identification 
of potentially lethal prostate cancer. J Clin Oncol, 2012. 30(15): p. 1857-63. 
 
Coen, J.J., et al., Radical radiation for localized prostate cancer: local persistence of disease 
results in a late wave of metastases. J Clin Oncol, 2002. 20(15): p. 3199-205. 
Cox DR. Regression models and life tables. Journal of the Royal Statistical Society 1972;34:187-

NRG-GU003 
50  
Version Date: April 26, 2019   
202. 
 
Cozzarini, C., et al., Need for high radiation dose (>or=70 gy) in early postoperative irradiation 
after radical prostatectomy: a single-institution analysis of 334 high-risk, node-negative 
patients. int J Radiat Oncol Biol Phys, 2009. 75(4): p. 966-74. 
De Meerleer, G., et al., Salvage intensity-modulated radiotherapy for rising PSA after radical 
prostatectomy. Radiother Oncol, 2008. 89(2): p. 205-13. 
Dearnaley, D.P., et al., Escalated-dose versus standard-dose conformal radiotherapy in prostate 
cancer: first results from the MRC RT01 randomised controlled trial. Lancet Oncol, 
2007. 8(6): p. 475-87. 
Fairclough DL, Peterson HF, Cella D, Bonomi P. Comparison of several model-based methods 
for analysing incomplete quality of life data in cancer clinical trials. Stat Med. Mar 15-
Apr 15 1998;17(5-7):781-796. 
Fairclough D. Design and analysis of quality of life studies in clinical trials (2nd ed.). Boca 
Raton, FL: Chapman & Hall/CRC; 2010. 
Feigenberg SJ, Hanlon AL, Horwitz EM, Uzzo RG, Eisenberg D, Pollack A. Long-term 
androgen deprivation increases Grade 2 and higher late morbidity in prostate cancer 
patients treated with three-dimensional conformal radiation therapy. Int J Radiat Oncol 
Biol Phys. 2005 Jun 1;62(2):397-405.  
Feng, M., et al., Predictive factors for late genitourinary and gastrointestinal toxicity in patients 
with prostate cancer treated with adjuvant or salvage radiotherapy. int J Radiat Oncol 
Biol Phys, 2007. 68(5): p. 1417-23. 
Fine J, Gray R. A proportional hazards model for the subditribution of a competing risk. J Am 
Statist Assoc.1999;94:496-509. 
 
Freedland SJ. Adjuvant and salvage radiotherapy after prostatectomy: American Society of 
Clinical Oncology clinical practice guideline endorsement. J Clin Oncol. 2014 Dec 
1;32(34):3892-8. Epub 2014 Nov 3. 
 
Freidlin, B., E.L. Korn, and Gray, R. A general inefficacy interim monitoring rule for 
randomized clinical trials. Clin Trials, 2010. 7: p. 197-208. 
Fuks, Z., et al., The effect of local control on metastatic dissemination in carcinoma of the 
prostate: long-term results in patients treated with 125I implantation. int J Radiat Oncol 
Biol Phys, 1991. 21(3): p. 537-47. 
Ghia, A.J., D.C. Shrieve, and J.D. Tward, Adjuvant radiotherapy use and patterns of care 
analysis for margin-positive prostate adenocarcinoma with extracapsular extension: 
post-prostatectomy adjuvant radiotherapy: a SEER analysis. Urology, 2010. 76(5): p. 
1169-74. 

NRG-GU003 
51  
Version Date: April 26, 2019   
Glick HAD, Sonnad, S.S., Polsky, D.: Analyzing Censored cost. In: Economic Evaluation in 
Clinical Trials. Glick HA (ed.) Oxford, New York, NY, pp 123-139, 2015. 
GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012. 
2012  [cited 2014 Aug 12]; Available from: http://globocan.iarc.fr/Default.aspx. 
Goenka A, Magsanoc JM, Pei X, Schechter M, Kollmeier M, Cox B, Scardino PT, Eastham JA, 
Zelefsky MJ. Long-term outcomes after high-dose postprostatectomy salvage radiation 
treatment. Int J Radiat Oncol Biol Phys. 2012 Sep 1;84(1):112-8.  
Gray R. A class of K-sample tests for comparing the cumulative incidence of a competing risk. 
Ann Stat  1988;16:1141-1154. 
 
Hall, E.J. and A.J. Giaccia, Radiobiology for the Radiologist2012: Wolters Kluwer Health. 
Hamilton, A.S., et al., Trends in the treatment of localized prostate cancer using supplemented 
cancer registry data. BJU Int, 2011. 107(4): p. 576-84. 
 
Harrison, A., et al., Potential for dose escalation in the post-prostatectomy setting with intensity-
modulated radiation therapy: a dosimetric study using EORTC consensus guidelines for 
target volume contours. Practical Radiation Oncology, 2011. 1(2): p. 105-114. 
Hoffman, K.E., et al., Recommendations for post-prostatectomy radiation therapy in the United 
States before and after the presentation of randomized trials. J Urol, 2011. 185(1): p. 
116-20. 
Hunter, G.K., et al., Late toxicity after intensity modulated and image guided radiation therapy 
for localized prostate cancer and post-prostatectomy patients. Practical Radiation 
Oncology, 2012. 
Kaplan EL, Meier P. Non-parameteric estimation from incomplete observations. Journal 
American Statistical Association 1958;53:457-481. 
Konski A, Sherman E, Krahn M, et al.: Economic analysis of a phase III clinical trial evaluating 
the addition of total androgen suppression to radiation versus radiation alone for locally 
advanced prostate cancer (Radiation Therapy Oncology Group protocol 86-10). Int J 
Radiat Oncol Biol Phys 63: 788-794, 2005. 
Konski A, Speier W, Hanlon A, Beck JR and Pollack A: Is proton beam therapy cost effective in 
the treatment of adenocarcinoma of the prostate? J Clin Oncol 25: 3603-3608, 2007. 
Konski A, Watkins-Bruner D, Brereton H, Feigenberg S and Hanks G: Long-term hormone 
therapy and radiation is cost-effective for patients with locally advanced prostate 
carcinoma. Cancer 106: 51-57, 2006. 
Konski A, Watkins-Bruner D, Feigenberg S, et al.: Using decision analysis to determine the cost-
effectiveness of intensity-modulated radiation therapy in the treatment of intermediate 
risk prostate cancer. Int J Radiat Oncol Biol Phys 66: 408-415, 2006. 

NRG-GU003 
52  
Version Date: April 26, 2019   
Kruser, T.J., et al., Early hypofractionated salvage radiotherapy for post-prostatectomy 
biochemical recurrence. Cancer, 2011. 117(12): p. 2629-36. 
Kuban, D., A. El-Mahdi, and P. Schellhammer, I-125 interstitial implantation for prostate 
cancer. Cancer, 1989. 63: p. 2415-2420. 
Kuban, D.A., A.M. el-Mahdi, and P.F. Schellhammer, Effect of local tumor control on distant 
metastasis and survival in prostatic adenocarcinoma. Urology, 1987. 30(5): p. 420-6. 
Kuban, D.A., et al., Long-term failure patterns and survival in a randomized dose-escalation 
trial for prostate cancer. Who dies of disease? int J Radiat Oncol Biol Phys, 2011. 79(5): 
p. 1310-7. 
Kuban, D.A., et al., Long-term results of the M. D. Anderson randomized dose-escalation trial 
for prostate cancer. Int J Radiat Oncol Biol Phys, 2008. 70(1): p. 67-74. 
Kupelian, P.A., et al., Hypofractionated intensity-modulated radiotherapy (70 gy at 2.5 gy per 
fraction) for localized prostate cancer: cleveland clinic experience. Int J Radiat Oncol 
Biol Phys, 2007. 68(5): p. 1424-30. 
Kupelian, P.A., et al., Hypofractionated intensity-modulated radiotherapy (70 gy at 2.5 Gy per 
fraction) for localized prostate cancer: long-term outcomes. Int J Radiat Oncol Biol 
Phys, 2005. 63(5): p. 1463-8. 
Lan, K. and E. DeMets, Discrete sequential boundaries for clinical trials. Biometrika, 1983. 70: 
p. 659-663. 
Lawton CA, Bae K, Pilepich M, Hanks G, Shipley W. Long-term treatment sequelae after 
external beam irradiation with or without hormonal manipulation for adenocarcinoma of 
the prostate: analysis of radiation therapy oncology group studies 85-31, 86-10, and 92-
02. Int J Radiat Oncol Biol Phys. 2008 Feb 1;70(2):437-41. Epub 2007 Sep 19.  
Leborgne, F., et al., Later outcomes and alpha/beta estimate from hypofractionated conformal 
three-dimensional radiotherapy versus standard fractionation for localized prostate 
cancer. int J Radiat Oncol Biol Phys, 2012. 82(3): p. 1200-7.  
Lee WR, Dignam JJ, Amin M, et al. NRG Oncology RTOG 0415: A randomized phase 3 
noninferiority study comparing 2 fractionation schedules in patients with low-risk 
prostate cancer.  Int J Radiat Oncol Biol Phys. Volume 94, Issue 1, 1 January 2016, 
pages 3-4. 
Little RA. Modeling the Drop-out Mechanism in Repeated-Measures Studies. J Am Stat Assoc. 
1995;90(431):1112-1121.  
 
Mantel N. Evaluation of survival data and two new rank order statistics arising in its 
consideration. Cancer Chemother Rep 1966;50:163-170. 
O'Brien, P.C. and T.R. Fleming, A multiple testing procedure for clinical trials. Biometrics, 

NRG-GU003 
53  
Version Date: April 26, 2019   
1979. 35(3): p. 549-56. 
Pinkawa, M., et al., Health-related quality of life after adjuvant and salvage postoperative 
radiotherapy for prostate cancer - a prospective analysis. Radiother Oncol, 2008. 88(1): 
p. 135-9. 
Pollack, A., et al., Dosimetry and preliminary acute toxicity in the first 100 men treated for 
prostate cancer on a randomized hypofractionation dose escalation trial. Int J Radiat 
Oncol Biol Phys, 2006. 64(2): p. 518-26. 
Pollack, A., Walker, G., Buyyounouski, M., Horwitz, E., Price, R., Feigenberg, S., Konski, A., 
Stoyanova, R., Ma, C., Five Year Results of a Randomized External Beam Radiotherapy 
Hypofractionation Trial for Prostate Cancer  int J Radiat Oncol Biol Phys, 2011. 81(2): 
p. S1. 
Prostate Cancer (Version 2.2016). 2014  [cited 2016 May 17]; Available from: 
http://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf. 
 
Proust-Lima, C., et al., Confirmation of a low alpha/beta ratio for prostate cancer treated by 
external beam radiation therapy alone using a post-treatment repeated-measures model 
for PSA dynamics. Int J Radiat Oncol Biol Phys, 2011. 79(1): p. 195-201. 
Rizopoulos D. Joint models for longitudinal and time-to-event data with applications in R. Boca 
Raton, FL: Chapman & Hall/CRC; 2012. 
 
Roach M 3rd, DeSilvio M, Lawton C, Uhl V, Machtay M, Seider MJ, Rotman M, Jones C, 
Asbell SO, Valicenti RK, Han S, Thomas CR Jr, Shipley WS; Phase III trial comparing 
whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant 
combined androgen suppression: Radiation Therapy Oncology Group 9413. J Clin 
Oncol. 2003 May 15;21(10):1904-11. 
Shipley, J.W., et al., Initial Report of RTOG 9601: A Phase III Trial in Prostate Cancer: Anti-
androgen Therapy (AAT) with Bicalutamide during and after Radiation Therapy (RT) 
Improves Freedom from Progression and Reduces the Incidence of Metastatic Disease in 
Patients following Radical Prostatectomy (RP) with pT2-3, N0 Disease, and Elevated 
PSA Levels. International Journal of Radiation Oncology Biology Physics, 2010. 78(3): p. 
s27. 
Sineshaw HM, Gray PJ, Efstathiou JA, Jemal A. Declining Use of Radiotherapy for Adverse 
Features After Radical Prostatectomy: Results From the National Cancer Data Base. Eur 
Urol. 2015 Nov;68(5):768-74. doi: 10.1016/j.eururo.2015.04.003. Epub 2015 Apr 18. 
PubMed PMID: 25896124. 
Smith, B.D., et al., Fractionation for whole breast irradiation: an American Society for 
Radiation Oncology (ASTRO) evidence-based guideline. int J Radiat Oncol Biol Phys, 
2011. 81(1): p. 59-68. 
Stephenson, A.J., et al., Defining biochemical recurrence of prostate cancer after radical 

NRG-GU003 
54  
Version Date: April 26, 2019   
prostatectomy: a proposal for a standardized definition. J Clin Oncol, 2006. 24(24): p. 
3973-8. 
Stephenson, A.J., et al., Postoperative radiation therapy for pathologically advanced prostate 
cancer after radical prostatectomy. Eur Urol, 2012. 61(3): p. 443-51. 
Stephenson, A.J., et al., Predicting the outcome of salvage radiation therapy for recurrent 
prostate cancer after radical prostatectomy. J Clin Oncol, 2007. 25(15): p. 2035-41.  
Stephenson, A.J., et al., Salvage radiotherapy for recurrent prostate cancer after radical 
prostatectomy. JAMA, 2004. 291(11): p. 1325-32. 
Swanson, G.P., et al., Predominant treatment failure in post-prostatectomy patients is local: 
analysis of patterns of treatment failure in SWOG 8794. J Clin Oncol, 2007. 25(16): p. 
2225-9. 
Swanson, G.P., et al., Update of SWOG 8794: Adjuvant Radiotherapy for pT3 Prostate Cancer 
Improves Metastasis Free Survival. Int J Radiat Biol, 2008. 72(1): p. S3. 
Tewari, A., et al., Positive surgical margin and perioperative complication rates of primary 
surgical treatments for prostate cancer: a systematic review and meta-analysis 
comparing retropubic, laparoscopic, and robotic prostatectomy. Eur Urol, 2012. 62(1): 
p. 1-15. 
Thompson, I.M., et al. Adjuvant and salvage radiotherapy after prostatectomy: AUA/ASTRO 
Guideline. J Urol. 2013. 190(2):441-9. Epub 2013 May 21. 
Thompson, I.M., et al., Adjuvant radiotherapy for pathological T3N0M0 prostate cancer 
significantly reduces risk of metastases and improves survival: long-term followup of a 
randomized clinical trial. J Urol, 2009. 181(3): p. 956-62. 
Thompson, I.M., Jr., et al., Adjuvant radiotherapy for pathologically advanced prostate cancer: 
a randomized clinical trial. Jama, 2006. 296(19): p. 2329-35. 
Valicenti, R.K., et al., Effect of higher radiation dose on biochemical control after radical 
prostatectomy for PT3N0 prostate cancer. int J Radiat Oncol Biol Phys, 1998. 42(3): p. 
501-6. 
Van der Kogel, A. and M. Joiner, Basic Clinical Radiobiology2009: Hodder Arnold. 
Van Der Poel, H.G., L. Moonen, and S. Horenblas, Sequential treatment for recurrent localized 
prostate cancer. J Surg Oncol, 2008. 97(5): p. 377-82. 
Verbeke G, Molenberghs G. Linear Mixed Models for Longitudinal Data. New York, NY: 
Springer-Verlag; 2000. 
Vogelius, I.R. and S.M. Bentzen, Meta-analysis of the Alpha/Beta Ratio for Prostate Cancer in 
the Presence of an Overall Time Factor: Bad News, Good News, or No News? int J 

NRG-GU003 
55  
Version Date: April 26, 2019   
Radiat Oncol Biol Phys, 2013. 85(1): p. 89-94. 
Whelan, T.J., et al., Long-term results of hypofractionated radiation therapy for breast cancer. N 
Engl J Med, 2010. 362(6): p. 513-20. 
Wiegel, T., et al., Achieving an undetectable PSA after radiotherapy for biochemical progression 
after radical prostatectomy is an independent predictor of biochemical outcome--results 
of a retrospective study. int J Radiat Oncol Biol Phys, 2009. 73(4): p. 1009-16. 
Wiegel, T., et al., Phase III postoperative adjuvant radiotherapy after radical prostatectomy 
compared with radical prostatectomy alone in pT3 prostate cancer with postoperative 
undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J Clin Oncol, 2009. 
27(18): p. 2924-30. 
Zelefsky, M.J., et al., Influence of local tumor control on distant metastases and cancer related 
mortality after external beam radiotherapy for prostate cancer. J Urol, 2008. 179(4): p. 
1368-73; discussion 1373. 
 
Zelen M. The randomization and stratification of patients to clinical tials. J Chron Dis. 27:365-
375, 1974. 
 
Zietman, A.L., et al., Randomized trial comparing conventional-dose with high-dose conformal 
radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from 
proton radiation oncology group/american college of radiology 95-09. J Clin Oncol, 2010. 
28(7): p. 1106-11.